var title_f42_53_43856="Algorithm for management of suspected fetomaternal hemorrhage";
var content_f42_53_43856=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73675&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73675&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Management of spontaneous fetomaternal hemorrhage (FMH)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 448px; height: 708px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     K-B: Kleihauer Betke; MOM: multiples of the median; MCA: middle cerebral artery.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_53_43856=[""].join("\n");
var outline_f42_53_43856=null;
var title_f42_53_43857="VSD with prolapsed RCC of aortic valve";
var content_f42_53_43857=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1196px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/69288/VSD_prolap_RCC_aort_movie.mp4?title=VSD+with+prolapsed+RCC+of+aortic+valve\" style=\"width:496px;height:384px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 580px\">",
"   <div class=\"ttl\">",
"    VSD with prolapsed RCC of aortic valve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 560px; height: 425px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The right coronary cusp of the aortic valve is seen prolapsing across the VSD and into the right ventricle. Note that the cusp is unusually elongated and more restricted in its motion when compared with the left coronary cusp.",
"    <div class=\"footnotes\">",
"     RV: right ventricle; LV: left ventricle; AO: aorta; MV: mitral valve; LA: left atrium; arrow: VSD.",
"     <br>",
"      * Denotes right coronary cusp of the aortic valve.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_53_43857=[""].join("\n");
var outline_f42_53_43857=null;
var title_f42_53_43858="Elbow ossification";
var content_f42_53_43858=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Secondary ossification centers of the elbow",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 437px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The appearance of the secondary ossification centers of the elbow proceeds in an orderly fashion, usually occurring approximately one year earlier in girls than in boys.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from DeLee, JC, Drez, D (Eds). Orthopaedic sports medicine: Principles and practice, W.B. Saunders, Philadelphia 1994. Copyright &copy; 1994 W.B. Saunders.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_53_43858=[""].join("\n");
var outline_f42_53_43858=null;
var title_f42_53_43859="Promethazine, phenylephrine, and codeine: Pediatric drug information";
var content_f42_53_43859=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Promethazine, phenylephrine, and codeine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?22/29/22997?source=see_link\">",
"    see \"Promethazine, phenylephrine, and codeine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/26/9638?source=see_link\">",
"    see \"Promethazine, phenylephrine, and codeine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F14854551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Warns of Codeine Use in Children After Tonsillectomy and/or Adenoidectomy",
"     </span>",
"     <span class=\"collapsible-date\">",
"      August 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The FDA has issued a Drug Safety Communication after reviewing reports of children who developed serious adverse effects, including death, after receiving codeine in the usual dosage range for pain relief following tonsillectomy and/or adenoidectomy for obstructive sleep apnea syndrome. Three deaths occurred in children that had evidence of a genetic variation (&ldquo;ultrarapid metabolizers&rdquo;) which results in faster and more complete conversion of codeine to morphine, possibly leading to overdose or death. The estimated incidence of this genetic variation is ~1-7 per 100 people, but may be higher in some ethnic groups.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Healthcare professionals should be aware of the risks associated with the administration of codeine or codeine-containing drugs in children after tonsillectomy and/or adenoidectomy for obstructive sleep apnea and should use the lowest effective dose for the least amount of time on an as-needed basis. Parents and caregivers who observe signs of overdose in a child such as unusual sleepiness, confusion, or difficult or noisy breathing should stop codeine administration and seek medical attention immediately.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm313631.htm#\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm313631.htm#",
"       </a>",
"       .",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1061480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihistamine/Decongestant Combination",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antitussive",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Cough Preparation",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1061475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?22/29/22997?source=see_link\">",
"      see \"Promethazine, phenylephrine, and codeine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &lt;6 years: Use of this combination is contraindicated in children &lt;6 years of age",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 6-11 years: 2.5-5 mL every 4-6 hours (maximum: 30 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 years and Adults: 5 mL every 4-6 hours (maximum: 30 mL/24 hours)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F214228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Syrup: Promethazine hydrochloride 6.25 mg, phenylephrine hydrochloride 5 mg, and codeine phosphate 10 mg per 5 mL (120 mL, 480 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F214218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F214248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-V",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1061484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with food or water to decrease GI upset. Administer with an accurate measuring device; do not use a household teaspoon (overdosage may occur).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1061483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief of coughs and upper respiratory symptoms including nasal congestion",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F4431139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1061486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to promethazine or other phenothiazines, codeine, phenylephrine, or any component; children &lt;6 years of age; asthma, peripheral vascular disease; hypertension; patients receiving MAO inhibitors",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1061474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with cardiovascular disease, narrow-angle glaucoma, prostatic hypertrophy, GI or GU obstruction, bone marrow depression, impaired liver function, hyperthyroidism, diabetes mellitus, peptic ulcer, sleep apnea, and hypertensive crisis; avoid in patients with suspected Reye's syndrome; promethazine may lower the seizure threshold; use with caution in patients with seizure disorders or receiving other medications which may also lower the seizure threshold; use with caution in patients with hypersensitivity reactions to morphine, hydrocodone, hydromorphone, levorphanol, oxycodone, oxymorphone. May cause orthostatic hypotension, use with caution in patients at risk of hypotension or where transient hypotensive episodes would be poorly tolerated (cardiovascular disease or cerebrovascular disease). May cause drowsiness and impair ability to perform hazardous activities requiring mental alertness. Promethazine has been reported to cause cholestatic jaundice. Use with caution in patients with two or more copies of the variant CYP2D6*2 allele (ie, CYP2D6 \"ultra-rapid metabolizers\"); these patients may have extensive conversion of codeine to morphine with resultant increased opioid-mediated effects.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1061473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid use in children &lt;6 years of age",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     , due to the potential for severe and potentially fatal respiratory depression associated with the combination of promethazine and other respiratory depressants (eg, codeine); fatalities associated with promethazine use alone in children &lt;2 years of age have also been reported. Dose should not be increased if cough does not respond; re-evaluate within 5 days for possible underlying pathology. Codeine is not recommended for cough control in patients with a productive cough. Neuroleptic malignant syndrome (NMS) has been reported with promethazine when used alone or in combination with antipsychotic drugs. May alter temperature regulation or mask toxicity of other drugs due to antiemetic effects.  May alter cardiac conduction (life-threatening arrhythmias have occurred with therapeutic doses of phenothiazines).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F214244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F214223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha1-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: May enhance the vasoconstricting effect of Phenylephrine (Systemic). Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of phenylephrine.  Use of hyaluronidase for other purposes in patients receiving phenylephrine may be considered as clinically indicated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1061487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increase fluids, fiber intake, and riboflavin in diet",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F214224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F214233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted with this combination. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1061479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/26/9638?source=see_link\">",
"      see \"Promethazine, phenylephrine, and codeine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth; may be habit-forming; do not discontinue abruptly. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12738 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.146-1B4384F6EC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_53_43859=[""].join("\n");
var outline_f42_53_43859=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14854551\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709353\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061480\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061475\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214228\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214218\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214248\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061484\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061483\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4431139\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061486\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061474\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061473\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214244\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214223\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061487\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214224\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214233\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061479\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12738\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12738|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?22/29/22997?source=related_link\">",
"      Promethazine, phenylephrine, and codeine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/26/9638?source=related_link\">",
"      Promethazine, phenylephrine, and codeine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_53_43860="Japanese encephalitis virus vaccine (inactivated): Pediatric drug information";
var content_f42_53_43860=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Japanese encephalitis virus vaccine (inactivated): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?39/38/40549?source=see_link\">",
"    see \"Japanese encephalitis virus vaccine (inactivated): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/56/14209?source=see_link\">",
"    see \"Japanese encephalitis virus vaccine (inactivated): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F185565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ixiaro&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13495796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ixiaro&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1020924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vaccine, Inactivated Virus",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1020936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?39/38/40549?source=see_link\">",
"      see \"Japanese encephalitis virus vaccine (inactivated): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixiaro&reg;: I.M.: Adults &ge;17 years of age: 0.5 mL/dose; a total of 2 doses given on days 0 and 28. Immunization should be completed &ge;7 days prior to potential exposure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Je-Vax&reg;: SubQ:",
"     <b>",
"      Note:",
"     </b>",
"     Available supplies are limited; use is restricted for children 1-16 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 1-2 years: Three 0.5 mL doses given on days 0, 7, and 30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;3 years and Adults: Three 1 mL doses given on days 0, 7, and 30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     An abbreviated schedule with the third dose administered on day 14 should be used only when time does not permit waiting; 2 doses a week apart produce immunity in about 80% of recipients; the longest regimen yields highest titers after 6 months.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Booster dose: Give after 2 years, or according to current recommendation. No information is available concerning the interchageabilitity of vaccines; however, because the supply of Je-Vax&reg; is limited, adults &ge;17 years of age who require a booster dose may receive a 2-dose primary series of Ixiaro&reg; when Je-Vax&reg; is not available and further vaccination is required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Travel should not commence for at least 10 days after the last dose of vaccine, to allow adequate antibody formation and recognition of any delayed adverse reaction",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F185555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ixiaro&reg;: Inactivated JEV proteins 6 mcg/0.5 mL (0.5 mL) [contains bovine serum, protamine sulfate, sodium metabisulfite]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F185543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1020940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ixiaro&reg;: I.M.: Shake well prior to use to form a homogeneous suspension. Do not use if discolored or if coarse particulate matter remains; inject I.M. into the deltoid muscle;",
"     <b>",
"      not for I.V., SubQ, or intradermal administration",
"     </b>",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Je-Vax&reg;:",
"     <b>",
"      SubQ:",
"     </b>",
"     Use entire contents of provided diluent to reconstitute vaccine; gently agitate to mix thoroughly; discard if powder does not dissolve; use within 8 hours following reconstitution;",
"     <b>",
"      not for I.V. , I.M., or intradermal administration",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1020935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixiaro&reg;: Refrigerate at 2&deg;C to 8&deg;C (35&deg;F to 46&deg;F); do not freeze; store in original packaging to protect from light.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Je-Vax&reg;: Refrigerate at 2&deg;C to 8&deg;C (35&deg;F to 46&deg;F); do not freeze; discard 8 hours after reconstitution.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1020925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Provide active immunity to Japanese encephalitis virus (Je-Vax&reg; FDA approved in children &ge;1 year and adults, Ixiaro&reg; FDA approved for use in patients &ge;17 years).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Japanese encephalitis vaccine is not recommended for all persons traveling to or residing in Asia. The Advisory Committee on Immunization Practices (ACIP) recommends vaccination for:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Persons spending &ge;1 month in endemic areas during transmission season.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Research laboratory workers who may be exposed to the Japanese encephalitis virus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccination may also be considered for the following:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Travel to areas with an ongoing outbreak",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Travelers planning to go outside of urban areas during transmission season and have an increased risk of exposure.  For example, high-risk activities include extensive outdoor activity in rural areas especially at night; extensive outdoor activities such as camping, hiking, etc; staying in accommodations without  air conditioning, screens or bed nets",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Travelers to endemic areas who are unsure of specific destination, activities, or duration of travel",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F185577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Report allergic or unusual adverse reactions to the Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Central nervous system: Fatigue, headache, pyrexia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Gastrointestinal: Diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Local: Injection site reaction: Edema, erythema, induration, pain, pruritus, tenderness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Neuromuscular &amp; skeletal: Back pain, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Respiratory: Cough, nasopharyngitis, pharyngolaryngeal pain, rhinitis, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Flu-like syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Encephalitis, neuritis, paresthesia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1020927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Ixiaro&reg;: Severe allergic reaction to a previous dose of the vaccine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Je-Vax&reg;: Hypersensitivity to the vaccine, any component, or to proteins of rodent or neural origin",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F3883890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The CDC recommends that the following individuals should not generally receive JE vaccine unless the benefit to the individual clearly outweighs the risk: Individuals acutely ill or with active infections, heart, kidney, or liver disorders, generalized malignancies such as leukemia or lymphoma, a history of multiple allergies, urticaria after hymenoptera envenomation, and pregnant women (unless there is a very high risk of Japanese encephalitis during the woman's stay in Asia). Routine prophylactic administration of acetaminophen to prevent fever due to vaccines has been shown to decrease the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Ixiaro&reg;: Contains protamine sulfate which may cause hypersensitivity reactions in certain individuals. Immunization should be completed &ge;7 days prior to potential exposure. Safety and efficacy have not been established in children &lt;17 years of age.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Je-Vax&reg;: Available supplies are limited. Use is restricted for children 1-16 years of age. Unusual alcohol intake immediately after vaccination has been associated with an increased incidence of hypersensitivity reactions; avoid excessive alcohol intake during the 48 hours following vaccination. Individuals receiving other vaccinations within 7 days prior to this vaccine also had an increased incidence of hypersensitivity reactions; where possible, JE vaccine should be administered concurrently with other vaccines.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1020928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immediate treatment for severe hypersensitivity reactions should be available during vaccine use.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Je-Vax&reg;: Severe adverse reactions manifesting as generalized urticaria or angioedema may occur within minutes following vaccination, or up to 17 days later; most reactions occur within 10 days, with the majority within 48 hours; observe vaccinees for 30 minutes after vaccination; warn them of the possibility of delayed generalized urticaria and to remain where medical care is readily available for 10 days following any dose of the vaccine. Due to the potential for severe adverse reactions, Japanese encephalitis (JE) vaccine is",
"     <b>",
"      not",
"     </b>",
"     recommended for all persons traveling to or residing in Asia. Use is not recommended for short-term travelers (&lt;30 days) who will not be outside of an urban area or when the visit is outside of a well-defined Japanese encephalitis virus transmission season. Safety and efficacy in infants &lt;1 year of age have not been established; therefore, immunization of infants should be deferred whenever possible; it is not known whether the vaccine is excreted in breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F185550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F185552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4104746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Risks of vaccine administration should be carefully considered and in general, pregnant women should only be vaccinated if they are at high risk for exposure. Infection from Japanese encephalitis during the first or second trimesters of pregnancy may increase risk of miscarriage. Intrauterine transmission of the Japanese encephalitis virus has been reported. To report inadvertent use of Ixiaro&reg; during pregnancy, contact Novartis Vaccines (800-244-7668).",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3883891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An inactivated vaccine which offers immunity to disease caused by the Japanese encephalitis virus. Je-Vax&reg; is prepared from the homogenate of infected mice brains. Ixiaro&reg; is a purified Japanese encephalitis vaccine made from the SA",
"     <sub>",
"      14",
"     </sub>",
"     -14-2 strain grown in Vero cells.",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1020941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/56/14209?source=see_link\">",
"      see \"Japanese encephalitis virus vaccine (inactivated): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse reactions may occur shortly after vaccination or up to 17 days (usually within 10 days) after vaccination; remain in areas with access to medical care for 10 days after receiving each dose if possible; advise concurrent use of other means to reduce the risk of mosquito exposure when possible, including bed nets, insect repellents, protective clothing, avoidance of travel in endemic areas, and avoidance of outdoor activity during twilight and evening periods",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1020943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ixiaro&reg; is a purified Japanese encephalitis vaccine made from the SA",
"     <sub>",
"      14",
"     </sub>",
"     -14-2 strain grown in Vero cells (JE-VC). It was developed due to neurologic side effects observed with Je-Vax&reg;, a vaccine derived from mice-brain cells (JE-MB) that contains additives which may contribute to the adverse effects. In studies comparing the two vaccines, seroconversion rates were similar following two doses of Ixiaro&reg; as opposed to three doses of Je-Vax&reg;. Safety profile of Ixiaro&reg; was found to be similar to placebo. Studies are currently planned to determine the need for booster doses following initial vaccination with Ixiaro&reg;.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Je-Vax&reg;: Production of Je-Vax&reg; was discontinued in 2006 and available supplies are limited.  Remaining supply is restricted for use in children 1-16 years of age. Contact Sanofi Pasteur to obtain remaining inventory.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Syncope After Vaccination-United States, January 2005-July 2007,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 57(17):457-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/53/43860/abstract-text/18451756/pubmed\" id=\"18451756\" target=\"_blank\">",
"        18451756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fischer M, Lindsey N, Staples JE, et al, \"Japanese Encephalitis Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-1):1-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/53/43860/abstract-text/20224546/pubmed\" id=\"20224546\" target=\"_blank\">",
"        20224546",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kroger AT, Atkinson WL, Marcuse EK, et al, \"General Recommendations on Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2006, 55(RR-15):1-48.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/53/43860/abstract-text/17136024/pubmed\" id=\"17136024\" target=\"_blank\">",
"        17136024",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, \"Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/53/43860/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13026 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-B5D3664DDB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_53_43860=[""].join("\n");
var outline_f42_53_43860=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185565\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13495796\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020924\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020936\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185555\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185543\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020940\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020935\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020925\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185577\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020927\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3883890\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020928\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299552\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185550\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185552\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4104746\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3883891\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020941\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1020943\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13026\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13026|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?39/38/40549?source=related_link\">",
"      Japanese encephalitis virus vaccine (inactivated): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/56/14209?source=related_link\">",
"      Japanese encephalitis virus vaccine (inactivated): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_53_43861="Histology healthy vs RP retina";
var content_f42_53_43861=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F67585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F67585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 568px\">",
"   <div class=\"ttl\">",
"    Histological appearance of healthy human retina (left) and retina of a patient with retinitis pigmentosa at a mid-stage of disease (right)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 548px; height: 292px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The space between the retinal pigment epithelium and the outer nuclear layer in the diseased retina is a processing artifact.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Hartong, DT, Berson, EL, Dryja, TP. Retinitis pigmentosa. The Lancet 2006; 368:1795. Copyright &copy;2006 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_53_43861=[""].join("\n");
var outline_f42_53_43861=null;
var title_f42_53_43862="Tuberculous enteritis";
var content_f42_53_43862=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tuberculous enteritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/53/43862/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/53/43862/contributors\">",
"     Louis-Michel Wong Kee Song, MD, FRCP(C)",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/53/43862/contributors\">",
"     Norman E Marcon, MD, FRCP(C)",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/53/43862/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/53/43862/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/53/43862/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/53/43862/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/53/43862/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extrapulmonary tuberculosis (TB) affects approximately 20 percent of TB cases in immunocompetent individuals and 50 percent of cases in HIV-positive patients. Tuberculous enteritis is a form of extrapulmonary TB that can involve any aspect of the gastrointestinal tract. It accounts for 1 to 3 percent of TB worldwide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/1\">",
"     1",
"    </a>",
"    ] and represents the sixth most frequent form of extra-pulmonary TB (after lymphatic, genitourinary, bone and joint, miliary, and meningeal tuberculosis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/2\">",
"     2",
"    </a>",
"    ]. The epidemiology of tuberculous enteritis varies widely around the globe, influenced in part by age, sex, socio-economic factors, immune status, and M. tuberculosis genotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/3\">",
"     3",
"    </a>",
"    ]. Young adults, primarily women, are mostly affected in regions like Pakistan, Turkey, and West Africa, whereas a lower disease incidence but similar or greater numbers of male patients are reported in studies from China, Singapore, India, and the United Kingdom [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to antituberculous therapy, gastrointestinal involvement was observed in 55 to 90 percent of patients with active pulmonary TB, but since has been observed in approximately 25 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to gastrointestinal TB will be reviewed here; issues related to other aspects of extrapulmonary TB are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/21/20826?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of tuberculous enteritis has been attributed to four mechanisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Swallowing infected sputum",
"     </li>",
"     <li>",
"      Hematogenous spread from active pulmonary or miliary TB",
"     </li>",
"     <li>",
"      Ingestion of contaminated milk or food",
"     </li>",
"     <li>",
"      Contiguous spread from adjacent organs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ileocecal region is the most common site of intestinal involvement. The affinity of M. tuberculosis for this site may be due to the relative stasis and abundant lymphoid tissue in this region. The organism penetrates the mucosa and localizes in the submucosal lymphoid tissue, where it initiates an inflammatory reaction with subsequent lymphangitis, endarteritis, granuloma formation, caseation necrosis, mucosal ulceration, and scarring.",
"   </p>",
"   <p>",
"    The macroscopic appearance of the intestinal lesions can be categorized as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ulcerative (60 percent), characterized by multiple superficial ulcers typically in a",
"      <span class=\"nowrap\">",
"       transverse/circumferential",
"      </span>",
"      orientation relative to the long axis of the gut lumen.",
"     </li>",
"     <li>",
"      Hypertrophic (10 percent), characterized by scarring, fibrosis, and pseudotumor lesions.",
"     </li>",
"     <li>",
"      Ulcerohypertrophic (30 percent), characterized by an inflammatory mass around the ileocecal valve with thickened and ulcerated intestinal walls. The ulcerohypertrophic form is more commonly observed in ileocecal disease than with TB involving other segments of the gastrointestinal tract.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms and signs of tuberculous enteritis are relatively vague and nonspecific. The presentation can be acute, chronic, or acute-on-chronic with a chronic presentation of weeks to months being most common. As a result, the diagnosis of ileocecal tuberculosis (TB) can be difficult and requires a high index of suspicion, especially in high-risk groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonspecific chronic abdominal pain is the most common symptom, occurring in 80 to 90 percent of patients. Anorexia, fatigue, fever, night sweats, weight loss, diarrhea, constipation, or blood in the stool may be present. A palpable right lower quadrant abdominal mass is present in 25 to 50 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The presence of ascites may help to distinguish ileocecal TB from Crohn's disease, since ascites is uncommon in Crohn&rsquo;s disease.",
"   </p>",
"   <p>",
"    Fistula and intestinal stricture may occur. Bowel obstruction is the most common complication and may be due to progressive stricture or adhesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine laboratory tests demonstrate mild anemia and increased sedimentation rate in 50 to 80 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/7\">",
"     7",
"    </a>",
"    ]. The white blood count is usually normal.",
"   </p>",
"   <p>",
"    A",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    is positive in the majority of patients with intestinal TB, but is of limited value because it does not differentiate between active disease and previous sensitization by contact or vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/7\">",
"     7",
"    </a>",
"    ]. Similarly, a positive interferon gamma release assay may be observed but cannot be used to distinguish between latent and active disease (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/10/20648?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnosis of latent tuberculosis infection in HIV-negative adults\", section on 'Tuberculin skin test'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/18/37160?source=see_link\">",
"     \"Interferon-gamma release assays for diagnosis of latent tuberculosis infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22015717\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral and intravenous contrast-enhanced computed tomography (CT) is the most helpful imaging modality to assess intraluminal and extraluminal pathology and extent of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. The most common CT finding is concentric mural thickening of the ileocecal region, with or without proximal intestinal dilatation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83833 \" href=\"mobipreview.htm?8/4/8260\">",
"     image 1",
"    </a>",
"    ). Occasionally asymmetric thickening of the medial cecal wall is seen. Characteristic lymphadenopathy with hypodense centers, representing caseous liquefaction, may be present in the adjacent mesentery. Findings more suggestive of TB than Crohn&rsquo;s disease (CD) include mural thickening with contiguous ileo-cecal valve involvement and hypodense lymph nodes with peripheral enhancement in the mesentery and retroperitoneum.",
"   </p>",
"   <p>",
"    Abdominal radiograph findings are generally nonspecific. Small bowel follow-through or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema may demonstrate mucosal ulcerations and strictures, a deformed cecum,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a gaping and incompetent ileocecal valve (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef85512 \" href=\"mobipreview.htm?29/40/30342\">",
"     image 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27981398\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;A presumptive diagnosis of tuberculous enteritis can be made in the setting of known active pulmonary tuberculosis (TB)",
"    <span class=\"nowrap\">",
"     (and/or",
"    </span>",
"    revealing chest x-ray), together with clinical, endoscopic,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiographic findings suggestive of intestinal TB. However, chest x-rays are positive (for active or healed TB) in less than 50 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/14-16\">",
"     14-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Definitive diagnosis is based on a combination of histology and culture of biopsy material; these can establish the diagnosis in up to 80 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/17\">",
"     17",
"    </a>",
"    ]. Colonoscopy with biopsy is the most useful nonoperative diagnostic procedure to obtain material for histology and culture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/14-16,18-20\">",
"     14-16,18-20",
"    </a>",
"    ]. In regions where available, a polymerase chain reaction (PCR) of biopsy specimens can facilitate diagnosis since it has higher sensitivity than routine culture, and results can be obtained within 48 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/3,21\">",
"     3,21",
"    </a>",
"    ]. Biopsy is also useful for investigation of the diseases that compose the differential diagnosis of TB enteritis. In the setting of ileocecal TB, endoscopic fine needle aspiration for cytology may be positive even if the biopsy is negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H27981325\">",
"     'Colonoscopy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H9\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27981325\">",
"    <span class=\"h2\">",
"     Colonoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonoscopic findings of ileocecal TB may include ulcers, strictures, nodules, pseudopolyps, fibrous bands, fistulas,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    deformed ileocecal valves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/23\">",
"     23",
"    </a>",
"    ]. The main differential diagnosis at endoscopy is CD. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The endoscopic finding of aphthous ulcers with normal surrounding mucosa, linear ulcers, or the presence of cobblestoning favors the diagnosis of CD; these lesions are rarely seen with TB. However, diffusely inflamed mucosa may be seen with severe inflammation due to CD. Ulcers due to TB tend to be circumferential (",
"    <a class=\"graphic graphic_picture graphicRef83831 \" href=\"mobipreview.htm?33/23/34163\">",
"     picture 1",
"    </a>",
"    ) and are usually surrounded by inflamed mucosa. A patulous valve with surrounding heaped up folds or a destroyed valve with a fish mouth opening is more likely to be caused by TB than CD (",
"    <a class=\"graphic graphic_picture graphicRef83832 \" href=\"mobipreview.htm?1/23/1398\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    TB granulomas are often submucosal; CD granulomas are typically mucosal, though submucosal granulomas may also be seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/24\">",
"     24",
"    </a>",
"    ]. Therefore, deep endoscopic biopsies should be taken from ulcers and their margins. Care must be taken to avoid perforation in the setting of significant inflammation or deep ulcerations.",
"   </p>",
"   <p>",
"    A TB isolation mask should be worn by all individuals in the endoscopy suite when a colonoscopy is performed on a patient for whom there is suspicion of intestinal TB.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22015934\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulomas associated with TB tend to be large and confluent, often with caseation necrosis. Ulcers are lined by aggregate epithelioid histiocytes, and disproportionate submucosal inflammation is seen. In contrast, granulomas associated with CD are infrequent, small, nonconfluent, and noncaseating. CD is also characterized by focally enhanced colitis and high prevalence of chronic inflammation in endoscopically normal appearing areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Typical histologic features of TB such as caseation granulomas and positive acid fast stain (AFB) are found in less than 33 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/15,23\">",
"     15,23",
"    </a>",
"    ]. Some histologic features that help differentiate TB enteritis from other etiologies include confluent granulomas, granulomas &gt;400 &micro;m in diameter, more than five granulomas in biopsies from one segment, and granulomas located in the submucosa or granulation tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of ileocecal TB includes CD, actinomycosis, histoplasmosis, amebiasis, yersiniosis, typhlitis, lymphoma, colon cancer, mucoceles, and drug-induced lesions (such as lesions due to nonsteroidal anti-inflammatory drugs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biopsy for culture and histopathology evaluation can be useful to definitively distinguish between these entities. The differentiation between CD and tuberculous enteritis is becoming increasingly important with the re-emergence of TB in Western countries in the wake of the AIDS epidemic, migration from developing countries, and the emergence of CD in Asian countries, possibly as a result of westernization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This distinction is also of utmost importance because the use of steroids or antitumor necrosis factor (anti-TNF) drugs in the setting of an incorrect diagnosis of CD may have disastrous consequences in patients with TB enteritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/7,11\">",
"     7,11",
"    </a>",
"    ]. However, there can be marked overlap between the features of CD and intestinal TB, making the differentiation between the two conditions difficult. A combination of clinical, radiographic, endoscopic, and biopsy findings are used to distinguish between them (",
"    <a class=\"graphic graphic_table graphicRef85948 \" href=\"mobipreview.htm?37/42/38572\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/13,28-32\">",
"     13,28-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one multivariate analysis involving 106 patients (53 with CD and 53 with intestinal TB), the presence of blood in stool, weight loss, focally enhanced colitis, and involvement of the sigmoid colon were the most important clinical features in differentiating CD from intestinal TB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/29\">",
"     29",
"    </a>",
"    ]. In another study involving 43 patients with confirmed diagnosis of intestinal TB and 53 patients with CD, night sweats, longitudinal ulcers, and granulomas were the most important clinical features to differentiate CD from intestinal TB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Clinical approach with uncertain diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of tuberculous enteritis can be difficult to establish. For situations in which there is a high index of suspicion based on clinical, radiographic, and endoscopic findings (in the absence of histological",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    microbiologic confirmation), many favor empiric initiation of antituberculous therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/6,14-16,19,34\">",
"     6,14-16,19,34",
"    </a>",
"    ]. Patients with tuberculous enteritis generally demonstrate clinical improvement within two weeks on empiric therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/35\">",
"     35",
"    </a>",
"    ], and in one study, colonoscopic follow-up after two to three months of anti-TB therapy showed complete healing of active ulcers and erosions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/36\">",
"     36",
"    </a>",
"    ]. In the absence of clinical response, surgical exploration may be warranted to evaluate for alternative diagnoses such as Crohn&rsquo;s disease, lymphoma, or malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, for situations in which the index of suspicion for tuberculous enteritis is moderate or low, and the diagnostic approach described above is unrevealing, laparoscopic exploration and possible laparotomy may be warranted to evaluate for alternative diagnoses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of intestinal tuberculosis (TB) depends upon the acuity of presentation and associated complications. In the presence of closed loop bowel obstruction, intestinal ischemia, bowel perforation, massive bleeding, or peritonitis, emergent surgical exploration with targeted treatment is warranted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/6,7,17\">",
"     6,7,17",
"    </a>",
"    ]. Subsequently antituberculous therapy should be initiated once the patient has stabilized from the operation. In the subacute setting, initiation of antituberculous therapy can result in a relatively prompt clinical response with improvement of symptoms in less than two weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/37\">",
"     37",
"    </a>",
"    ]. However, cases of worsening of strictures due to scar tissue formation have been reported.",
"   </p>",
"   <p>",
"    In general, the medical treatment of tuberculous enteritis is similar to treatment of pulmonary TB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/7\">",
"     7",
"    </a>",
"    ], with conventional antituberculous chemotherapy (RIPE: rifampicin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    ) for two months, followed by rifampicin plus isoniazid (RI) for an additional four to seven months. Most countries adhere to the World Health Organization guidelines of DOTS (directly observed treatment, short course) given on a daily or thrice weekly basis. In one prospective, randomized trial, both DOTS (RIPE thrice weekly for two months followed by RI thrice weekly for four months) and daily chemotherapy (RIPE for two months followed by RI for seven months) were equally effective at healing ileocecal and colonic tuberculosis in 79 and 75 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/35\">",
"     35",
"    </a>",
"    ]. The initiation of therapy, modification of the drug regimen based on drug susceptibility testing, and monitoring of therapy and drug toxicity are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/21/19802?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with low-grade obstruction and fistulas may respond to antituberculous therapy, and most with mild to moderate intestinal strictures can be managed nonoperatively. Bowel obstruction is the most common complication and may be due to progressive stricture or adhesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/10\">",
"     10",
"    </a>",
"    ]. Healing in the setting of antituberculous therapy can also result in symptomatic scarring. Those with multiple",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe strictures are less likely to respond to medical therapy, and surgical resection may be required for high-grade obstruction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/46/14058?source=see_link\">",
"     \"Small bowel obstruction: Causes and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/0/6152?source=see_link\">",
"     \"Principles of management of enteric fistulas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The surgical resection should be conservative; in some cases, multiple strictures of the small bowel may be amenable to strictureplasty to avoid major resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/17\">",
"     17",
"    </a>",
"    ]. Bypass surgery for obstructing lesions should be avoided because of complications related to blind loop syndrome. Colonoscopic balloon dilation may be an alternative to surgery; it may be used to manage symptomatic short ileal strictures although experience with this technique is limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43862/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18059196\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tuberculous enteritis can develop via swallowing infected sputum, hematogenous spread, ingestion of contaminated milk or food,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      contiguous spread from adjacent organs. The ileocecal region is the most common site of intestinal involvement of tuberculosis (TB), likely due to the relative stasis and abundant lymphoid tissue in this region. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations of tuberculous enteritis are relatively vague and nonspecific. Chronic abdominal pain is common. Anorexia, fatigue, fever, night sweats, weight loss, diarrhea, constipation, or blood in the stool may be present. A palpable right lower quadrant abdominal mass may be observed. Ascites may be present. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A presumptive diagnosis of tuberculous enteritis can be made in the setting of known active pulmonary TB",
"      <span class=\"nowrap\">",
"       (and/or",
"      </span>",
"      revealing chest x-ray), together with clinical, endoscopic,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiographic findings suggestive of intestinal TB. Definitive diagnosis is based on a combination of histology and culture of biopsy material. (See",
"      <a class=\"local\" href=\"#H27981398\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Colonoscopy with biopsy is the most useful nonoperative diagnostic procedure to obtain material for histology and culture. Colonoscopic findings of ileocecal TB may include ulcers, strictures, nodules, pseudopolyps, fibrous bands, fistulas,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      deformed ileocecal valves. (See",
"      <a class=\"local\" href=\"#H27981325\">",
"       'Colonoscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Computed tomography (CT) is the most helpful imaging modality to assess intraluminal and extraluminal pathology and extent of disease. The most common CT finding is concentric mural thickening of the ileocecal region, with or without proximal intestinal dilatation. (See",
"      <a class=\"local\" href=\"#H22015717\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of ileocecal TB includes Crohn&rsquo;s disease, actinomycosis, histoplasmosis, amebiasis, yersiniosis, typhlitis, lymphoma, colon cancer, mucoceles, and drug-induced lesions. Biopsy for culture and histopathology evaluation is the most useful tool to distinguish between these entities. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For situations in which there is high index of suspicion for tuberculous enteritis based on clinical, radiographic, and endoscopic findings (in the absence of histological",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      microbiologic confirmation), initiation of empiric antituberculous therapy is appropriate. Lack of clinical improvement after two weeks of empiric therapy should prompt reassessment; laparoscopic exploration",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      laparotomy for further evaluation of alternative diagnoses may be needed. For situations in which there is moderate or low index of suspicion for tuberculous enteritis, early laparotomy may be warranted for evaluation of alternative diagnoses before determination regarding empiric antituberculous therapy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical approach with uncertain diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, treatment of tuberculous enteritis is similar to treatment of pulmonary TB. Surgery is warranted for patients with complications such as perforation, massive bleeding,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      high-grade obstruction. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Management'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/21/19802?source=see_link\">",
"       \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/1\">",
"      Farer LS, Lowell AM, Meador MP. Extrapulmonary tuberculosis in the United States. Am J Epidemiol 1979; 109:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/2\">",
"      Dasgupta A, Singh N, Bhatia A. Abdominal tuberculosis: a histopathological study with special reference to intestinal perforation and mesenteric vasculopathy. J Lab Physicians 2009; 1:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/3\">",
"      Donoghue HD, Holton J. Intestinal tuberculosis. Curr Opin Infect Dis 2009; 22:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/4\">",
"      Haddad FS, Ghossain A, Sawaya E, Nelson AR. Abdominal tuberculosis. Dis Colon Rectum 1987; 30:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/5\">",
"      Marshall JB. Tuberculosis of the gastrointestinal tract and peritoneum. Am J Gastroenterol 1993; 88:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/6\">",
"      Horvath KD, Whelan RL. Intestinal tuberculosis: return of an old disease. Am J Gastroenterol 1998; 93:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/7\">",
"      Kapoor VK. Abdominal tuberculosis. Postgrad Med J 1998; 74:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/8\">",
"      Petrosyan M, Mason RJ. Tuberculous enteritis presenting as small-bowel obstruction. Clin Gastroenterol Hepatol 2006; 4:xxiii.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/9\">",
"      Garc&iacute;a-D&iacute;az RA, Ruiz-G&oacute;mez JL, Rodr&iacute;guez-Sanjuan JC, et al. Perforation of the colon caused by intestinal tuberculosis. Dis Colon Rectum 2006; 49:927; author reply 927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/10\">",
"      Ha HK, Ko GY, Yu ES, et al. Intestinal tuberculosis with abdominal complications: radiologic and pathologic features. Abdom Imaging 1999; 24:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/11\">",
"      Balthazar EJ, Gordon R, Hulnick D. Ileocecal tuberculosis: CT and radiologic evaluation. AJR Am J Roentgenol 1990; 154:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/12\">",
"      Suri S, Gupta S, Suri R. Computed tomography in abdominal tuberculosis. Br J Radiol 1999; 72:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/13\">",
"      Almadi MA, Ghosh S, Aljebreen AM. Differentiating intestinal tuberculosis from Crohn's disease: a diagnostic challenge. Am J Gastroenterol 2009; 104:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/14\">",
"      Bhargava DK, Kushwaha AK, Dasarathy S, et al. Endoscopic diagnosis of segmental colonic tuberculosis. Gastrointest Endosc 1992; 38:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/15\">",
"      Shah S, Thomas V, Mathan M, et al. Colonoscopic study of 50 patients with colonic tuberculosis. Gut 1992; 33:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/16\">",
"      Misra SP, Misra V, Dwivedi M, Gupta SC. Colonic tuberculosis: clinical features, endoscopic appearance and management. J Gastroenterol Hepatol 1999; 14:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/17\">",
"      Aston NO. Abdominal tuberculosis. World J Surg 1997; 21:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/18\">",
"      Kalvaria I, Kottler RE, Marks IN. The role of colonoscopy in the diagnosis of tuberculosis. J Clin Gastroenterol 1988; 10:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/19\">",
"      Singh V, Kumar P, Kamal J, et al. Clinicocolonoscopic profile of colonic tuberculosis. Am J Gastroenterol 1996; 91:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/20\">",
"      Kim KM, Lee A, Choi KY, et al. Intestinal tuberculosis: clinicopathologic analysis and diagnosis by endoscopic biopsy. Am J Gastroenterol 1998; 93:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/21\">",
"      Anand BS, Schneider FE, El-Zaatari FA, et al. Diagnosis of intestinal tuberculosis by polymerase chain reaction on endoscopic biopsy specimens. Am J Gastroenterol 1994; 89:2248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/22\">",
"      Kochhar R, Rajwanshi A, Goenka MK, et al. Colonoscopic fine needle aspiration cytology in the diagnosis of ileocecal tuberculosis. Am J Gastroenterol 1991; 86:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/23\">",
"      Alvares JF, Devarbhavi H, Makhija P, et al. Clinical, colonoscopic, and histological profile of colonic tuberculosis in a tertiary hospital. Endoscopy 2005; 37:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/24\">",
"      Kirsch R, Pentecost M, Hall Pde M, et al. Role of colonoscopic biopsy in distinguishing between Crohn's disease and intestinal tuberculosis. J Clin Pathol 2006; 59:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/25\">",
"      Pulimood AB, Ramakrishna BS, Kurian G, et al. Endoscopic mucosal biopsies are useful in distinguishing granulomatous colitis due to Crohn's disease from tuberculosis. Gut 1999; 45:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/26\">",
"      Pulimood AB, Peter S, Ramakrishna B, et al. Segmental colonoscopic biopsies in the differentiation of ileocolic tuberculosis from Crohn's disease. J Gastroenterol Hepatol 2005; 20:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/27\">",
"      Dilauro S, Crum-Cianflone NF. Ileitis: when it is not Crohn's disease. Curr Gastroenterol Rep 2010; 12:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/28\">",
"      Lee YJ, Yang SK, Byeon JS, et al. Analysis of colonoscopic findings in the differential diagnosis between intestinal tuberculosis and Crohn's disease. Endoscopy 2006; 38:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/29\">",
"      Makharia GK, Srivastava S, Das P, et al. Clinical, endoscopic, and histological differentiations between Crohn's disease and intestinal tuberculosis. Am J Gastroenterol 2010; 105:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/30\">",
"      Gabellec MM, Panzanelli P, Sasso&egrave;-Pognetto M, Lledo PM. Synapse-specific localization of vesicular glutamate transporters in the rat olfactory bulb. Eur J Neurosci 2007; 25:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/31\">",
"      Li X, Liu X, Zou Y, et al. Predictors of clinical and endoscopic findings in differentiating Crohn's disease from intestinal tuberculosis. Dig Dis Sci 2011; 56:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/32\">",
"      Pulimood AB, Amarapurkar DN, Ghoshal U, et al. Differentiation of Crohn's disease from intestinal tuberculosis in India in 2010. World J Gastroenterol 2011; 17:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/33\">",
"      Yu H, Liu Y, Wang Y, et al. Clinical, endoscopic and histological differentiations between Crohn's disease and intestinal tuberculosis. Digestion 2012; 85:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/34\">",
"      Wagner TE, Huseby ES, Huseby JS. Exacerbation of Mycobacterium tuberculosis enteritis masquerading as Crohn's disease after treatment with a tumor necrosis factor-alpha inhibitor. Am J Med 2002; 112:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/35\">",
"      Tony J, Sunilkumar K, Thomas V. Randomized controlled trial of DOTS versus conventional regime for treatment of ileocecal and colonic tuberculosis. Indian J Gastroenterol 2008; 27:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/36\">",
"      Park YS, Jun DW, Kim SH, et al. Colonoscopy evaluation after short-term anti-tuberculosis treatment in nonspecific ulcers on the ileocecal area. World J Gastroenterol 2008; 14:5051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/37\">",
"      Giouleme O, Paschos P, Katsaros M, et al. Intestinal tuberculosis: a diagnostic challenge--case report and review of the literature. Eur J Gastroenterol Hepatol 2011; 23:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43862/abstract/38\">",
"      Bhasin DK, Sharma BC, Dhavan S, et al. Endoscopic balloon dilation of ileal stricture due to tuberculosis. Endoscopy 1998; 30:S44.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2688 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-61.234.146.186-EA4EE1DDAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_53_43862=[""].join("\n");
var outline_f42_53_43862=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18059196\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22015717\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27981398\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27981325\">",
"      Colonoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22015934\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Clinical approach with uncertain diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18059196\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2688\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2688|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?8/4/8260\" title=\"diagnostic image 1\">",
"      CT tuberculous enteritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?29/40/30342\" title=\"diagnostic image 2\">",
"      TB enteritis - barium enema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2688|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/23/34163\" title=\"picture 1\">",
"      Ascending colon TB enteritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/23/1398\" title=\"picture 2\">",
"      Ileocecal tuberculous enteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2688|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/42/38572\" title=\"table 1\">",
"      Distinguishing Crohns vs intestinal TB",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/21/20826?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/10/20648?source=related_link\">",
"      Diagnosis of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/18/37160?source=related_link\">",
"      Interferon-gamma release assays for diagnosis of latent tuberculosis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/0/6152?source=related_link\">",
"      Principles of management of enteric fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/46/14058?source=related_link\">",
"      Small bowel obstruction: Causes and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/21/19802?source=related_link\">",
"      Treatment of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_53_43863="Amphotericin B (conventional): Drug information";
var content_f42_53_43863=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Amphotericin B (conventional): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?36/30/37348?source=see_link\">",
"    see \"Amphotericin B (conventional): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/12/201?source=see_link\">",
"    see \"Amphotericin B (conventional): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F7254335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F134687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Fungizone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F134709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antifungal Agent, Parenteral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F134690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:  Premedication:",
"     </b>",
"     For patients who experience infusion-related immediate reactions, premedicate with the following drugs 30-60 minutes prior to drug administration: NSAID &plusmn; diphenhydramine",
"     <b>",
"      or",
"     </b>",
"     acetaminophen with diphenhydramine",
"     <b>",
"      or",
"     </b>",
"     hydrocortisone. If the patient experiences rigors during the infusion, meperidine may be administered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Test dose:",
"     </b>",
"     I.V.: 1 mg infused over 20-30 minutes. Many clinicians believe a test dose is unnecessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Susceptible fungal infections:",
"     </b>",
"     I.V.: Adults: 0.3-1.5 mg/kg/day; 1-1.5 mg/kg over 4-6 hours every other day may be given once therapy is established; aspergillosis, rhinocerebral mucormycosis, often require 1-1.5 mg/kg/day; do not exceed 1.5 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Aspergillosis, disseminated:",
"     </b>",
"     I.V.: 0.6-0.7 mg/kg/day for 3-6 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Bone marrow transplantation (prophylaxis):",
"     </b>",
"     I.V.: Low-dose amphotericin B 0.1-0.25 mg/kg/day has been administered after bone marrow transplantation to reduce the risk of invasive fungal disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Candidemia (neutropenic or non-neutropenic):",
"     </b>",
"     I.V.: 0.5-1 mg/kg/day until 14 days after first negative blood culture and resolution of signs and symptoms (Pappas, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Candidiasis, chronic, disseminated:",
"     </b>",
"     I.V.: 0.5-0.7 mg/kg/day for 3-6 months and resolution of radiologic lesions (Pappas, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Dematiaceous fungi:",
"     </b>",
"     I.V.: 0.7 mg/kg/day in combination with an azole",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Endocarditis:",
"     </b>",
"     I.V.: 0.6-1 mg/kg/day (with or without flucytosine) for 6 weeks after valve replacement;",
"     <b>",
"      Note:",
"     </b>",
"     If isolates susceptible and/or clearance demonstrated, guidelines recommend step-down to fluconazole; also for long-term suppression therapy if valve replacement is not possible (Pappas, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Endophthalmitis, fungal:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Intravitreal (unlabeled use): 10 mcg in 0.1 mL (in conjunction with systemic therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V.: 0.7-1 mg/kg/day (with or without flucytosine) for at least 4-6 weeks (Pappas, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Esophageal candidiasis:",
"     </b>",
"     I.V.: 0.3-0.7 mg/kg/day for 14-21 days after clinical improvement (Pappas, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Histoplasmosis:",
"     </b>",
"     Chronic, severe pulmonary or disseminated: I.V.: 0.5-1 mg/kg/day for 7 days, then 0.8 mg/kg every other day (or 3 times/week) until total dose of 10-15 mg/kg; may continue itraconazole as suppressive therapy (lifelong for immunocompromised patients)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Meningitis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Candidal:",
"     </i>",
"     I.V.: 0.7-1 mg/kg/day (with or without flucytosine) for at least 4 weeks;",
"     <b>",
"      Note:",
"     </b>",
"     Liposomal amphotericin favored by IDSA guidelines based on decreased risk of nephrotoxicity and potentially better CNS penetration (Pappas, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Cryptococcal or Coccidioides:",
"     </i>",
"     I.T.: Initial: 0.01-0.05 mg as single daily dose; may increase daily in increments of 0.025-0.1 mg as tolerated (maximum: 1.5 mg/day; most patients will tolerate a maximum dose of ~0.5 mg/treatment). Once titration to a maximum tolerated dose is achieved, that dose is administered daily. Once CSF improvement noted, may decrease frequency on a weekly basis (eg, 5 times/week, then 3 times/week, then 2 times/week, then once weekly, then once every other week, then once every 2 weeks, etc) until administration occurs once every 6 weeks. Typically, concurrent oral azole therapy is maintained (Stevens, 2001).",
"     <b>",
"      Note:",
"     </b>",
"     IDSA notes that the use of I.T. amphotericin for cryptococcal meningitis is generally discouraged and rarely necessary (Perfect, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Histoplasma:",
"     </i>",
"     I.V.: 0.5-1 mg/kg/day for 7 days, then 0.8 mg/kg every other day (or 3 times/week) for 3 months total duration; follow with fluconazole suppressive therapy for up to 12 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Meningoencephalitis, cryptococcal (Perfect, 2010):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      HIV positive:",
"     </i>",
"     Induction: 0.7-1 mg/kg/day (plus flucytosine 100 mg/kg/day) for 2 weeks, then change to oral fluconazole for at least 8 weeks; alternatively, amphotericin (0.7-1 mg/kg/day) may be continued uninterrupted for 4-6 weeks; maintenance: amphotericin 1 mg/kg/week for &ge;1 year may be considered, but inferior to use of azoles",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      HIV negative:",
"     </i>",
"     Induction: 0.7-1 mg/kg/day (plus flucytosine 100 mg/kg/day) for 2 weeks (low-risk patients), &ge;4 weeks (non-low-risk, but without neurologic complication, immunosuppression, underlying disease, and negative CSF culture at 2 weeks), &gt;6 weeks (neurologic complication or patients intolerant of flucytosine) Follow with azole consolidation/maintenance treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Oropharyngeal candidiasis:",
"     </b>",
"     I.V.: 0.3 mg/kg/day for 7-14 days (Pappas, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Osteoarticular candidiasis:",
"     </b>",
"     I.V.: 0.5-1 mg/kg/day for several weeks, followed by fluconazole for 6-12 months (osteomyelitis) or 6 weeks (septic arthritis) (Pappas, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Penicillium marneffei:",
"      </i>",
"     </b>",
"     I.V.: 0.6 mg/kg/day for 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Pneumonia: Cryptococcal",
"     </b>",
"     (mild-to-moderate): I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      HIV positive:",
"     </i>",
"     0.5-1 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      HIV negative:",
"     </i>",
"     0.5-0.7 mg/kg/day (plus flucytosine) for 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Sporotrichosis:",
"     </b>",
"     Pulmonary, meningeal, osteoarticular or disseminated: I.V.: Total dose of 1-2 g, then change to oral itraconazole or fluconazole for suppressive therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Urinary tract candidiasis",
"     </b>",
"     (Pappas, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Fungus balls:",
"     </i>",
"     I.V.: 0.5-0.7 mg/kg/day with or without flucytosine 25 mg/kg 4 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Pyelonephritis:",
"     </i>",
"     I.V.: 0.5-0.7 mg/kg/day with or without flucytosine 25 mg/kg 4 times daily for 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Symptomatic cystitis:",
"     </i>",
"     I.V.: 0.3-0.6 mg/kg/day for 1-7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      Bladder irrigation:",
"     </i>",
"     Irrigate with 50 mcg/mL solution instilled periodically or continuously for 5-10 days or until cultures are clear for fluconazole-resistant",
"     <i>",
"      Candida",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F134703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/12/201?source=see_link\">",
"      see \"Amphotericin B (conventional): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:  Premedication:",
"     </b>",
"     For patients who experience infusion-related immediate reactions, premedicate with the following drugs 30-60 minutes prior to drug administration: NSAID &plusmn; with or without diphenhydramine",
"     <b>",
"      or",
"     </b>",
"     acetaminophen with diphenhydramine",
"     <b>",
"      or",
"     </b>",
"     hydrocortisone. If the patient experiences rigors during the infusion, meperidine may be administered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Test dose:",
"     </b>",
"     I.V.: Infants and Children: 0.1 mg/kg/dose to a maximum of 1 mg; infuse over 30-60 minutes. Many clinicians believe a test dose is unnecessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Susceptible fungal infections:",
"     </b>",
"     I.V.: Infants and Children: Maintenance dose: 0.25-1 mg/kg/day given once daily; infuse over 2-6 hours. Once therapy has been established, amphotericin B can be administered on an every-other-day basis at 1-1.5 mg/kg/dose; cumulative dose: 1.5-2 g over 6-10 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Duration of therapy varies with nature of infection: Usual duration is 4-12 weeks or cumulative dose of 1-4 g.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Indication-specific dosing:",
"     </b>",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Aspergillosis (HIV-exposed/-positive):",
"     </b>",
"     I.V.: 1-1.5 mg/kg/day once daily (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Candidiasis (HIV-exposed/-positive):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Invasive: I.V.: 0.5-1.5 mg/kg/day once daily (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Esophageal: I.V.: 0.3-0.5 mg/kg/day once daily (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oropharyngeal, refractory: I.V.: 0.3-0.5 mg/kg/day (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Coccidioidomycosis (HIV-exposed/-positive):",
"     </b>",
"     I.V.: 0.5-1 mg/kg/day (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Cryptococcus,",
"      </i>",
"     </b>",
"     <b>",
"      CNS disease (HIV-exposed/-positive):",
"     </b>",
"     I.V.: 0.7-1 mg/kg/day plus flucytosine;",
"     <b>",
"      Note:",
"     </b>",
"     Minimum 2 week induction followed by consolidation and chronic suppressive therapy; may increase amphotericin dose to 1.5 mg/kg/day if flucytosine is not tolerated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Cryptococcus,",
"      </i>",
"     </b>",
"     <b>",
"      disseminated (non-CNS disease) or severe pulmonary disease (HIV-exposed/-positive):",
"     </b>",
"     I.V.: 0.7-1 mg/kg/day once daily with or without flucytosine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Histoplasma, CNS or severe disseminated:",
"     </b>",
"     I.V.: 1 mg/kg/day once daily (CDC, 2009)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F134691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F134692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     If renal dysfunction is due to the drug, the daily total can be decreased by 50% or the dose can be given every other day. I.V. therapy may take several months.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal replacement therapy: Poorly dialyzed; no supplemental dose or dosage adjustment necessary, including patients on intermittent hemodialysis or CRRT.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis (PD): Administration in dialysate: 1-2 mg/L of peritoneal dialysis fluid either with or without low-dose I.V. amphotericin B (a total dose of 2-10 mg/kg given over 7-14 days). Precipitate may form in ionic dialysate solutions.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F134665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as desoxycholate: 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F134650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F747024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     May be infused over 4-6 hours. For a patient who experiences chills, fever, hypotension, nausea, or other nonanaphylactic infusion-related reactions, premedicate with the following drugs 30-60 minutes prior to drug administration: A nonsteroidal (eg, ibuprofen, choline magnesium trisalicylate) &plusmn; diphenhydramine",
"     <b>",
"      or",
"     </b>",
"     acetaminophen with diphenhydramine",
"     <b>",
"      or",
"     </b>",
"     hydrocortisone. If the patient experiences rigors during the infusion, meperidine may be administered. Bolus infusion of normal saline immediately preceding, or immediately preceding and following amphotericin B may reduce drug-induced nephrotoxicity. Risk of nephrotoxicity increases with amphotericin B doses &gt;1 mg/kg/day. Infusion of admixtures more concentrated than 0.25 mg/mL should be limited to patients absolutely requiring volume contraction.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F134716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;display:inline\">",
"     Solution:  Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W;",
"     <b>",
"      incompatible",
"     </b>",
"     with D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     R, LR, R, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Aldesleukin, amiodarone, tacrolimus, teniposide, thiotepa, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Allopurinol, amifostine, Aminosyn&reg; II, amsacrine, anidulafungin, aztreonam, bivalirudin, caspofungin, cefepime, dexmedetomidine, docetaxel, doxorubicin liposomal, enalaprilat, etoposide phosphate, fenoldopam, filgrastim, fludarabine, FreAmine&reg; III, gemcitabine, granisetron, hetastarch in lactate electrolyte injection (Hextend&reg;), linezolid, melphalan, meropenem, ondansetron, paclitaxel, pantoprazole, pemetrexed, piperacillin/tazobactam, propofol, tigecycline, vinorelbine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Cefpirome, cisatracurium, doripenem, fluconazole, foscarnet, magnesium sulfate, remifentanil, sargramostim.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Heparin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F134669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of severe systemic and central nervous system infections caused by susceptible fungi such as",
"     <i>",
"      Candida",
"     </i>",
"     species,",
"     <i>",
"      Histoplasma capsulatum",
"     </i>",
"     ,",
"     <i>",
"      Cryptococcus neoformans",
"     </i>",
"     ,",
"     <i>",
"      Aspergillus",
"     </i>",
"     species,",
"     <i>",
"      Blastomyces dermatitidis",
"     </i>",
"     ,",
"     <i>",
"      Torulopsis glabrata",
"     </i>",
"     , and",
"     <i>",
"      Coccidioides immitis",
"     </i>",
"     ; fungal peritonitis; irrigant for bladder fungal infections; used in fungal infection in patients with bone marrow transplantation, amebic meningoencephalitis, ocular aspergillosis (intraocular injection), candidal cystitis (bladder irrigation), chemoprophylaxis (low-dose I.V.), immunocompromised patients at risk of aspergillosis (intranasal/nebulized), refractory meningitis (intrathecal), coccidioidal arthritis (intra-articular/I.M.).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Low-dose amphotericin B has been administered after bone marrow transplantation to reduce the risk of invasive fungal disease.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F134718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (intrathecal administration) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Conventional amphotericin formulations (Amphocin&reg;, Fungizone&reg;) may be confused with lipid-based formulations (AmBisome&reg;, Abelcet&reg;, Amphotec&reg;).",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Large overdoses have occurred when conventional formulations were dispensed inadvertently for lipid-based products. Single daily doses of conventional amphotericin formulation never exceed 1.5 mg/kg.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F134707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Systemic:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension, tachypnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever, chills, headache (less frequent with I.T.), malaise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypokalemia, hypomagnesemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, nausea (less frequent with I.T.), vomiting (less frequent with I.T.), diarrhea, heartburn, cramping epigastric pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Normochromic-normocytic anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Pain at injection site with or without phlebitis or thrombophlebitis (incidence may increase with peripheral infusion of admixtures)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Generalized pain, including muscle and joint pains (less frequent with I.T.)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Decreased renal function and renal function abnormalities including azotemia, renal tubular acidosis, nephrocalcinosis (&gt;0.1 mg/mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension, flushing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Delirium, arachnoiditis, pain along lumbar nerves (especially I.T. therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukocytosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (especially with I.T. therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute liver failure, agranulocytosis, anuria, arrhythmias, bone marrow suppression, bronchospasm, cardiac arrest, cardiac failure, coagulation defects, convulsions, diplopia, dyspnea, eosinophilia, hearing loss, hemorrhagic gastroenteritis, hepatitis, hypersensitivity pneumonitis, increased liver function tests, jaundice, leukoencephalopathy, leukopenia, maculopapular rash, melena, nephrogenic diabetes insipidus, oliguria, peripheral neuropathy, pruritus, pulmonary edema, renal failure, renal tubular acidosis, shock, skin exfoliation, Stevens-Johnson syndrome,  thrombocytopenia, tinnitus, toxic epidermal necrolysis, transient vertigo, ventricular fibrillation, vision changes, wheezing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F134672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to amphotericin or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F134654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis: Has been reported with amphotericin B-containing drugs; facilities for cardiopulmonary resuscitation should be available during administration due to the possibility of anaphylactic reaction. If severe respiratory distress occurs, the infusion should be immediately discontinued; during the initial dosing, the drug should be administered under close clinical observation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infusion reactions: Acute reactions (eg, fever, shaking chills, hypotension, anorexia, nausea, vomiting, headache, tachypnea) may occur 1-3 hours after starting an intravenous infusion. These reactions are usually more common with the first few doses and generally diminish with subsequent doses. Avoid rapid infusion to prevent hypotension, hypokalemia, arrhythmias, and shock.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Leukoencephalopathy: Has been reported following administration of amphotericin. Total body irradiation has been reported to be a possible predisposition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nephrotoxicity: May cause nephrotoxicity; usual risk factors include underlying renal disease, concomitant nephrotoxic medications and daily and/or cumulative dosing of amphotericin. Avoid use with other nephrotoxic drugs; drug-induced renal toxicity usually improves with interrupting therapy, decreasing dosage, or increasing dosing interval. However permanent impairment may occur, especially in patients receiving large cumulative dose (eg, &gt;5 g) and in those also receiving other nephrotoxic drugs. Hydration and sodium repletion prior to administration may reduce the risk of developing nephrotoxicity. Frequent monitoring of renal function is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fungal infections:",
"     <b>",
"      [U.S. Boxed Warning]: Should be used primarily for treatment of progressive, potentially life-threatening fungal infections, not noninvasive forms of infection.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neutropenic patients: Pulmonary reactions may occur in neutropenic patients receiving leukocyte transfusions; separation of the infusions as much as possible is advised.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Error prevention:",
"     <b>",
"      [U.S. Boxed warning]: Verify the product name and dosage if dose exceeds 1.5 mg/kg.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Therapy interruption: If therapy is stopped for &gt;7 days, restart at the lowest dose recommended  and increase gradually.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F134659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Amphotericin B may enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May diminish the therapeutic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: Amphotericin B may enhance the nephrotoxic effect of Colistimethate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Amphotericin B may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flucytosine: Amphotericin B may enhance the adverse/toxic effect of Flucytosine. This may be related to the adverse effects of amphotericin B on renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gallium Nitrate: Amphotericin B may enhance the nephrotoxic effect of Gallium Nitrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saccharomyces boulardii: Antifungal Agents may diminish the therapeutic effect of Saccharomyces boulardii.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F134661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13314057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Amphotericin crosses the placenta and enters the fetal circulation. No teratogenic or undue systemic toxicity (electrolyte imbalance or renal dysfunction) has been reported in the mother or fetus. Toxic maternal effects are to be expected and must be monitored (Perfect, 2010). Amphotericin B is recommended for the treatment of serious systemic fungal diseases in pregnant women. Refer to current guidelines (King, 1998).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F134698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13314058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if amphotericin is excreted into breast milk. Due to its poor oral absorption, systemic exposure to the nursing infant is expected to be decreased; however, because of the potential for toxicity, breast-feeding is not recommended (Mactal-Haaf, 2001).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Amphotericin B Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (1): $45.60",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F134663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     BUN and serum creatinine levels should be determined every other day when therapy is increased and at least weekly thereafter. Renal function (monitor frequently during therapy), electrolytes (especially potassium and magnesium), liver function tests, temperature, PT/PTT, CBC; monitor input and output; monitor for signs of hypokalemia (muscle weakness, cramping, drowsiness, ECG changes, etc)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F134675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ampho-Moronal (DE);",
"     </li>",
"     <li>",
"      Amphocil (MX);",
"     </li>",
"     <li>",
"      Ampholin (TH);",
"     </li>",
"     <li>",
"      Ampholip (PH);",
"     </li>",
"     <li>",
"      Amphotec (AR);",
"     </li>",
"     <li>",
"      Amphotret (PH, TH);",
"     </li>",
"     <li>",
"      Anfotericina B (DO, GT, PA);",
"     </li>",
"     <li>",
"      Fungilin Lozenges (AU);",
"     </li>",
"     <li>",
"      Fungizon (BR, CN, HN);",
"     </li>",
"     <li>",
"      Fungizone (AU, BE, CH, CO, FI, FR, GR, IE, IN, IT, KE, NG, NL, NO, NZ, PE, PL, SE, TR, TW, TZ, UY, VE, ZA);",
"     </li>",
"     <li>",
"      Terix (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F134653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to ergosterol altering cell membrane permeability in susceptible fungi and causing leakage of cell components with subsequent cell death. Proposed mechanism suggests that amphotericin causes an oxidation-dependent stimulation of macrophages (Lyman, 1992).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F134671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Minimal amounts enter the aqueous humor, bile, CSF (inflamed or noninflamed meninges), pericardial fluid, pleural fluid, and synovial fluid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Biphasic: Initial: 15-48 hours; Terminal: 15 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Within 1 hour following a 4- to 6-hour dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (2% to 5% as biologically active form); ~40% eliminated over a 7-day period and may be detected in urine for at least 7 weeks after discontinued use",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Arsura EL, Ismail Y, Freedman S, et al, &ldquo;Amphotericin B-Induced Dilated Cardiomyopathy,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 1994, 97(6):560-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/53/43863/abstract-text/7985716/pubmed\" id=\"7985716\" target=\"_blank\">",
"        7985716",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Benson JM and Nahata MC, &ldquo;Clinical Use of Systemic Antifungal Agents,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1988, 7(6):424-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/53/43863/abstract-text/3042267/pubmed\" id=\"3042267\" target=\"_blank\">",
"        3042267",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Benson JM and Nahata MC, &ldquo;Pharmacokinetics of Amphotericin B in Children,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1989, 33(11):1989-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/53/43863/abstract-text/2610508/pubmed\" id=\"2610508\" target=\"_blank\">",
"        2610508",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Branch RA, &ldquo;Prevention of Amphotericin B-Induced Renal Impairment. A Review on the Use of Sodium Supplementation,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1988, 148(11):2389-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/53/43863/abstract-text/3056312/pubmed\" id=\"3056312\" target=\"_blank\">",
"        3056312",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children: Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/53/43863/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cruz JM, Peacock JE Jr, Loomer L, et al, &ldquo;Rapid Intravenous Infusion of Amphotericin B: A Pilot Study,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 1992, 93:123-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/53/43863/abstract-text/1497007/pubmed\" id=\"1497007\" target=\"_blank\">",
"        1497007",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Devuyst O, Goffin E, and Van Ypersele de Strihou C, &ldquo;Recurrent Hemiparesis Under Amphotericin B for",
"      <i>",
"       Candida albicans",
"      </i>",
"      Peritonitis,&rdquo;",
"      <i>",
"       Nephrol Dial Transplant",
"      </i>",
"      , 1995, 10(5):699-701.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/53/43863/abstract-text/7566587/pubmed\" id=\"7566587\" target=\"_blank\">",
"        7566587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gales MA and Gales BJ, &ldquo;Rapid Infusion of Amphotericin B in Dextrose,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1995, 29(5):523-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/53/43863/abstract-text/7655137/pubmed\" id=\"7655137\" target=\"_blank\">",
"        7655137",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gallis HA, Drew RH, and Pickard WW, &ldquo;Amphotericin B: 30 Years of Clinical Experience,&rdquo;",
"      <i>",
"       Rev Infect Dis",
"      </i>",
"      , 1990, 12(2):308-29.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/53/43863/abstract-text/2184499/pubmed\" id=\"2184499\" target=\"_blank\">",
"        2184499",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goodwin SD, Cleary JD, Walawander CA, et al, &ldquo;Pretreatment Regimens for Adverse Events Related to Infusion of Amphotericin B,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 1995, 20(4):755-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/53/43863/abstract-text/7795069/pubmed\" id=\"7795069\" target=\"_blank\">",
"        7795069",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gould FK, Denning DW, Elliott TS, et al, &ldquo;Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults:  A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 2012, 67(2):269-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/53/43863/abstract-text/22086858/pubmed\" id=\"22086858\" target=\"_blank\">",
"        22086858",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jeffery GM, Beard ME, Ikram RB, et al, &ldquo;Intranasal Amphotericin B Reduces the Frequency of Invasive Aspergillosis in Neutropenic Patients,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 1991, 90(6):685-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/53/43863/abstract-text/2042684/pubmed\" id=\"2042684\" target=\"_blank\">",
"        2042684",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jones RS, Barman A, Suh B, et al, &ldquo;Successful Treatment of",
"      <i>",
"       Aspergillus vertebral",
"      </i>",
"      Osteomyelitis With Amphotericin B Lipid Complex,&rdquo;",
"      <i>",
"       Infect Dis Clin Pract",
"      </i>",
"      , 1995, 4:237-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      King CT, Rogers PD, Cleary JD, et al, \"Antifungal Therapy During Pregnancy,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 1998, 27(5):1151-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/53/43863/abstract-text/9827262/pubmed\" id=\"9827262\" target=\"_blank\">",
"        9827262",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kintzel PE and Smith GH, &ldquo;Practical Guidelines for Preparing and Administering Amphotericin B,&rdquo;",
"      <i>",
"       Am J Hosp Pharm",
"      </i>",
"      , 1992, 49(5):1156-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/53/43863/abstract-text/1595747/pubmed\" id=\"1595747\" target=\"_blank\">",
"        1595747",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Koren G, Lau A, Klein J, et al, &ldquo;Pharmacokinetics and Adverse Effects of Amphotericin B in Infants and Children,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1988, 113(3):559-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/53/43863/abstract-text/3411404/pubmed\" id=\"3411404\" target=\"_blank\">",
"        3411404",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lyman CA and Walsh TJ, &ldquo;Systemically Administered Antifungal Agents. A Review of Their Clinical Pharmacology and Therapeutic Applications,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1992, 44(1):9-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/53/43863/abstract-text/1379913/pubmed\" id=\"1379913\" target=\"_blank\">",
"        1379913",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mactal-Haaf C, Hoffman M, and Kuchta A, \"Use of Anti-infective Agents During Lactation, Part 3: Antivirals, Antifungals, and Urinary Antiseptics,\"",
"      <i>",
"       J Hum Lact",
"      </i>",
"      , 2001, 17(2):160-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/53/43863/abstract-text/11847833/pubmed\" id=\"11847833\" target=\"_blank\">",
"        11847833",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mohr J, Johnson M, Cooper T, et al, &ldquo;Current Options in Antifungal Pharmacotherapy,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2008, 28(5):614-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/53/43863/abstract-text/18447660/pubmed\" id=\"18447660\" target=\"_blank\">",
"        18447660",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pappas PG, Kauffman CA, Andes D, et al, &ldquo;Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 48(5):503-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/53/43863/abstract-text/19191635/pubmed\" id=\"19191635\" target=\"_blank\">",
"        19191635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Patel R, &ldquo;Antifungal Agents. Part I. Amphotericin B Preparations and Flucytosine,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1998, 73(12):1205-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/53/43863/abstract-text/9868423/pubmed\" id=\"9868423\" target=\"_blank\">",
"        9868423",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perfect JR, Dismukes WE, Dromer F, et al, &ldquo;Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2010, 50(3):291-322.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/53/43863/abstract-text/20047480/pubmed\" id=\"20047480\" target=\"_blank\">",
"        20047480",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rex JH, Bennett JE, Sugar AM, &ldquo;A Randomized Trial Comparing Fluconazole With Amphotericin B for the Treatment of Candidemia in Patients Without Neutropenia. Candidemia Study Group and the National Institute,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1994, 331(20):1325-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/53/43863/abstract-text/7935701/pubmed\" id=\"7935701\" target=\"_blank\">",
"        7935701",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rex JH, Walsh TJ, Sobel JD, et al, &ldquo;Practice Guidelines for the Treatment of Candidiasis. Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2000, 30(4):662-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/53/43863/abstract-text/10770728/pubmed\" id=\"10770728\" target=\"_blank\">",
"        10770728",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Slain D, &ldquo;Lipid-Based Amphotericin B for the Treatment of Fungal Infections,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1999, 19(3):306-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/53/43863/abstract-text/10221369/pubmed\" id=\"10221369\" target=\"_blank\">",
"        10221369",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stevens DA and Shatsky SA, \"Intrathecal Amphotericin in the Management of Coccidioidal Meningitis,\"",
"      <i>",
"       Semin Respir Infect",
"      </i>",
"      , 2001, 16(4):263-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/53/43863/abstract-text/11740828/pubmed\" id=\"11740828\" target=\"_blank\">",
"        11740828",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      The Ad Hoc Advisory Panel on Peritonitis Management. &ldquo;Continuous Ambulatory Peritoneal Dialysis (CAPD) Peritonitis Treatment Recommendations: 1989 Update,&rdquo;",
"      <i>",
"       Perit Dial Int",
"      </i>",
"      , 1989, 9(4):247-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/53/43863/abstract-text/2488376/pubmed\" id=\"2488376\" target=\"_blank\">",
"        2488376",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8701 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C50D28AF5E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_53_43863=[""].join("\n");
var outline_f42_53_43863=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7254335\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134687\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134709\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134690\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134703\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134691\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134692\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134665\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134650\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F747024\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134716\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134669\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134718\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134707\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134672\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134654\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298744\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134659\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134661\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13314057\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134698\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13314058\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322986\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134663\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134675\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134653\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134671\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8701\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8701|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?36/30/37348?source=related_link\">",
"      Amphotericin B (conventional): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/12/201?source=related_link\">",
"      Amphotericin B (conventional): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_53_43864="Maternal nutrition during lactation";
var content_f42_53_43864=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Maternal nutrition during lactation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/53/43864/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/53/43864/contributors\">",
"     Nancy F Butte, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/53/43864/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/53/43864/contributors\">",
"     Steven A Abrams, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/53/43864/contributors\">",
"     Kathleen J Motil, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/53/43864/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/53/43864/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/53/43864/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mother's capacity to produce milk of sufficient quantity and quality to support infant growth is resilient and remarkably resistant to nutritional deprivation. However, milk production normally affects maternal body composition and nutritional status, and lactating women have increased nutrient demands.",
"   </p>",
"   <p>",
"    The changes in maternal nutritional status during lactation, effect of maternal nutrition on milk volume and composition, and nutrient requirements of lactating women are reviewed here. Additional aspects of breastfeeding are discussed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MATERNAL NUTRITIONAL STATUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lactation is supported partially by mobilization of tissue stores. This, in turn, affects maternal weight and nutritional status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Body weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postpartum weight changes in lactating women are highly variable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/1\">",
"     1",
"    </a>",
"    ]. Mild, gradual weight loss typically occurs during the first six months postpartum. Average weight loss in this period is greater in affluent than poor populations (0.8 versus 0.1 kg per month). These differences are thought to depend upon differences in weight gain in pregnancy, cultural practices, level of physical activity, and availability of food.",
"   </p>",
"   <p>",
"    Gestational weight gain is the most consistent and strongest predictor of postpartum weight change in most studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Other factors that contribute to weight loss after pregnancy include prepregnancy weight, age, parity, race, smoking, exercise, return to work outside the home, and lactation.",
"   </p>",
"   <p>",
"    Data are conflicting on the effect of breastfeeding on postpartum weight changes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most studies indicate that lactation has little effect [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/3-8\">",
"       3-8",
"      </a>",
"      ]. As an example, among 7116 in the Collaborative Perinatal Study, the interpregnancy weight change was similar between breastfeeding and nonbreastfeeding women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In some reports, weight loss was less in lactating than nonlactating women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/2,9-11\">",
"       2,9-11",
"      </a>",
"      ]. In a series from the Netherlands, the overall increase in body mass nine months postpartum was similar to nonpregnant women of the same age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/11\">",
"       11",
"      </a>",
"      ]. However, women who breastfed longer than two months gained 0.6",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      more than the nonpregnant women, while nonlactating women lost body mass.",
"     </li>",
"     <li>",
"      Some studies report more weight loss in lactating women than nonlactating women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/12-14\">",
"       12-14",
"      </a>",
"      ]. In one report, for example, women who breastfed longer than 12 months lost more weight between 1 and 12 months postpartum compared to women who did not breastfeed or breastfed for &le;3 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Lean body mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although some women may lose weight while breastfeeding, the lean body mass of well-nourished women is preserved during the first six months of lactation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/15\">",
"     15",
"    </a>",
"    ]. This is thought to result from an adaptive response of protein metabolism when dietary protein is restricted so that body protein degradation is reduced more than synthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Vitamins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fat and water-soluble vitamins are secreted into milk. Therefore, the dietary requirement for most vitamins is increased during lactation. A chronically deficient diet will deplete maternal vitamin stores.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Bone mineral loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone mineral content declines during lactation, and compensatory remineralization occurs after weaning and resumption of menses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. Changes in calcium, phosphorus, and magnesium homeostasis are independent of maternal dietary intake.",
"   </p>",
"   <p>",
"    Several small case-control studies suggested that previous lactation reduced the later risk of osteoporosis and bone fracture in elderly women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. As an example, in a report of women &ge;65 years in Australia, the risk of hip fracture was lower in parous women who had breastfed (odds ratio 0.47) compared to never breastfed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/23\">",
"     23",
"    </a>",
"    ]. Other larger epidemiologic studies did not confirm this association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/24-26\">",
"     24-26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MILK VOLUME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Healthy exclusively breastfeeding women produce approximately 750 to 800 mL per day of milk when lactation is fully established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/27\">",
"     27",
"    </a>",
"    ]. However, milk volume varies among individuals and can range from 450 to 1200 mL per day.",
"   </p>",
"   <p>",
"    Milk volume is low on the first two days postpartum, increases markedly on days three and four, then gradually increases to levels seen in full lactation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/28\">",
"     28",
"    </a>",
"    ]. Milk volume has a wider range during later lactation because the timing of weaning varies among individuals. In a cohort of healthy infants, average (range) volumes at 6, 9, and 12 months of age were 769 (335 to 1144), 637 (205 to 1185), and 445 (27 to 1154) mL per day, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Infant demand",
"    </span>",
"    &nbsp;&mdash;&nbsp;Milk production is determined mostly by infant demand rather than maternal lactation capacity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/29\">",
"     29",
"    </a>",
"    ]. This is illustrated by the ability of mothers to successfully breastfeed twins or triplets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/30\">",
"     30",
"    </a>",
"    ]. Factors that influence the volume of milk consumed are the infant's current weight, weight gain, birth weight, and gender [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/28,31-33\">",
"     28,31-33",
"    </a>",
"    ]. However, the frequency or duration of feeding do not correlate with milk volumes during the period of exclusive breastfeeding when the milk supply is adequate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/34\">",
"     34",
"    </a>",
"    ]. The addition of milk substitutes or solid foods reduces milk production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Maternal factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal factors influence milk volume. Maternal stress, anxiety, fatigue, illness, and smoking can decrease milk production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. In one report, for example, milk production at two weeks postpartum was lower in smoking than nonsmoking mothers of preterm infants (406 versus 514 mL per day) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/38\">",
"     38",
"    </a>",
"    ]. Incomplete breast emptying and infrequent milk expression can also reduce volume [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In well-nourished women, age, parity, current weight, body mass index, body fat, and weight gain during pregnancy do not influence milk production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/32,42,43\">",
"     32,42,43",
"    </a>",
"    ]. However, milk volumes in poor women in developing countries (approximately 525 to 885 mL per day) are similar or less than those in developed countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/44-51\">",
"     44-51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aerobic exercise does not affect milk volume. In a randomized trial, volume and composition of breast milk and infant weight gain were similar for exercising lactating women and controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/52\">",
"     52",
"    </a>",
"    ]. Cardiovascular fitness improved in the exercising women.",
"   </p>",
"   <p>",
"    Combined",
"    <span class=\"nowrap\">",
"     estrogen/progesterone",
"    </span>",
"    oral contraceptives moderately inhibit milk volume. In one report, combined oral contraceptives resulted in reduced milk production (42 percent decrease) compared to progestin only or controls (12 and 6 percent, respectively), although infant growth was similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/53\">",
"     53",
"    </a>",
"    ]. The authors suggested that more prolonged or intense feeding periods or supplementary feedings may have compensated for the reduced milk volume and sustained growth.",
"   </p>",
"   <p>",
"    Skin-to-skin holding of preterm infants in newborn intensive care units may increase milk production in their mothers. In one study, daily milk volume increased in mothers performing skin-to-skin holding compared to historical controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MILK COMPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lactation requires additional energy and nutrients from the diet. Milk quality is usually sufficient to support infant growth, even when the mother's dietary supply of energy and nutrients is limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/27\">",
"     27",
"    </a>",
"    ]. However, a chronically deficient diet can deplete maternal nutrient stores and adversely affect milk composition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Energy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduced maternal energy intake appears to have a limited effect on milk volume, unless dietary deprivation is extreme [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/42,50\">",
"     42,50",
"    </a>",
"    ]. In one study, dietary restriction to 1500 kcal per day for one week did not reduce milk production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/55\">",
"     55",
"    </a>",
"    ]. However, daily milk volume decreased 15 percent when less than 1500 kcal per day were consumed.",
"   </p>",
"   <p>",
"    Moderate weight loss with or without exercise does not adversely affect lactation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. In one study, lactating women were randomly assigned to an 11-day program of diet, diet plus exercise, or control at 12 weeks postpartum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/57\">",
"     57",
"    </a>",
"    ]. Weight loss averaged 1.9, 1.6, and 0.2 kg in the three groups, respectively, while milk volume and composition and infant weight gain were similar during the short study period.",
"   </p>",
"   <p>",
"    Longer periods of dieting are also well tolerated. In one report, 22 of 33 women who completed a 10-week weight reduction program lost an average of 5 kg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/56\">",
"     56",
"    </a>",
"    ]. Daily milk production was similar at baseline and 10 weeks (759 versus 802 mL), and infants gained an average of 21 gm per day. In another study, overweight lactating women were randomly assigned to reduce energy intake by 500 kcal per day and exercise for 45 minutes four times per week or to maintain their usual diet and limit exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/59\">",
"     59",
"    </a>",
"    ]. Women in the diet and exercise group lost more weight (4.8 versus 0.8 kg) and fat mass (4.0 versus 0.3) than controls. Infant weight gain was similar, although the statistical power to detect a difference in weight gain was limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal diet typically does not affect the quantity or quality of milk protein, even in malnourished populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. However, protein supplementation increases milk protein concentration, and free amino acid and urea content parallels the quantity and quality of maternal dietary protein. In one study, for example, nitrogen concentration was measured in three lactating women given a low or high (46 versus 134 g per day) protein diet for four days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/63\">",
"     63",
"    </a>",
"    ]. Concentrations of total nitrogen, protein, and nonprotein nitrogen were greater with the high protein diet. The higher concentration of nonprotein nitrogen was due to the increased levels of urea and free amino acids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Fatty acids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type and proportion of dietary fat affects the type but not quantity of fatty acids in human milk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. A low fat diet increases the fraction of milk lipids endogenously synthesized by the mammary gland. In one study, mammary gland fat synthesis was measured in five lactating women given a low or high fat diet (5 versus 40 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/66\">",
"     66",
"    </a>",
"    ]. Medium chain fatty acid secretion in milk fat was greater on the low than high fat diet (16.3 versus 12.8 percent).",
"   </p>",
"   <p>",
"    Consumption of partially hydrogenated fats and oils also influences the fatty acid composition of milk. As an example, linoleic acid concentration was higher in milk from vegan mothers than omnivore controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/67\">",
"     67",
"    </a>",
"    ]. However, diet does not appear to affect the cholesterol and phospholipid content of human milk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Fat-soluble vitamins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concentration of fat-soluble vitamins in milk is reduced in maternal vitamin deficiency and increases following supplementation. As an example, vitamin A levels in milk were lower than normal in Navajo mothers with suboptimal nutrition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vitamin D levels in milk also reflect maternal intake. In one study, vitamin D concentrations were undetectable in milk from mothers with vitamin D deficiency but increased with supplementation and ultraviolet light [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/69\">",
"     69",
"    </a>",
"    ]. In another report, pharmacologic doses of ergocalciferol (2500 mcg) resulted in toxic levels in milk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/70\">",
"     70",
"    </a>",
"    ]. Similar to the other fat-soluble vitamins, vitamin K concentration in milk depends upon maternal dietary intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Water-soluble vitamins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concentration of water-soluble vitamins in milk also depends upon maternal diet and is reduced with vitamin deficiency. However, concentration of water-soluble vitamins in milk is regulated to not exceed a specific threshold [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. Vitamin C and thiamine (vitamin B1) concentrations, for example, remain below approximately 160",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    and 200",
"    <span class=\"nowrap\">",
"     mcg/L,",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/72-74\">",
"     72-74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vitamin content in milk is reduced in vitamin-deficient states and responds to supplementation. In thiamine deficiency (beriberi), for example, the thiamin content of human milk is low. Vitamin B6 (pyridoxine) concentration in milk also responds rapidly to changes in maternal intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Folate is preferentially secreted into milk. However, milk concentrations are reduced in severe folate deficiency and increase after folate supplementation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/76\">",
"     76",
"    </a>",
"    ]. Vitamin B12 content in milk is also reduced with deficiency that may occur in vegans, malnourished women, and women with latent pernicious anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Mineral content",
"    </span>",
"    &nbsp;&mdash;&nbsp;The levels of most inorganic components of human milk are independent of maternal diet or serum concentrations, although intake of some trace minerals affects milk levels. Concentrations of calcium, phosphorus, and magnesium in milk are independent of maternal serum levels and are not greatly influenced by variations in dietary intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/78\">",
"     78",
"    </a>",
"    ]. Iron, copper, and zinc levels in human milk are also independent of maternal nutrient status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/79-82\">",
"     79-82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    concentration in milk correlated with maternal plasma concentration, which was influenced by diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/83\">",
"     83",
"    </a>",
"    ]. Breast milk iodine concentration also depends upon dietary intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     NUTRIENT REQUIREMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutritional requirements to support lactation are high and exceed those in pregnancy and the nonpregnant state (",
"    <a class=\"graphic graphic_table graphicRef81797 \" href=\"mobipreview.htm?16/32/16909\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Energy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The energy cost of exclusive breastfeeding from birth through six months postpartum is 500",
"    <span class=\"nowrap\">",
"     kcal/day.",
"    </span>",
"    This estimate is based upon the average volume of milk produced (780 mL per day), the average energy content of milk (67",
"    <span class=\"nowrap\">",
"     kcal/100",
"    </span>",
"    mL) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/86\">",
"     86",
"    </a>",
"    ]. In well-nourished women, the energy cost of lactation is subsidized by mobilization of tissue stores (approximately 170 kcal per day). Therefore, the recommended dietary allowance (RDA) for energy is 330 kcal per day more than nonpregnant, nonlactating women.",
"   </p>",
"   <p>",
"    From 7 through 12 months of age, maternal weight stability is assumed. Based on an average milk production of 600 mL per day and the same energy content, the additional energy required for lactation is 400 kcal per day. The additional energy required for lactation is added to the estimated energy requirement (EER) for normal-weight women using current age, weight, and physical activity level (PAL).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;The additional protein requirement for the first six months of lactation is 25 g per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/86\">",
"     86",
"    </a>",
"    ]. This RDA is based upon the volume of milk (780 mL per day), the average protein content of milk (1",
"    <span class=\"nowrap\">",
"     g/100",
"    </span>",
"    mL), and an efficiency of utilization of dietary protein for milk synthesis of 47 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Fat-soluble vitamins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lactation does not appear to increase vitamin D requirements. Both lactating and nonlactating women require 5.0 mcg (200 IU) per day of vitamin D when sunlight exposure is inadequate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/87\">",
"     87",
"    </a>",
"    ]. Much higher doses of Vitamin D supplementation to the lactating mother, up to 4000 IU daily, have been shown to decrease the likelihood of rickets in the breastfed infant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/88\">",
"     88",
"    </a>",
"    ]. However, current recommendations are for supplementation of all breast-fed infants (200 IU daily) rather than for supplementation of the lactating mother.",
"   </p>",
"   <p>",
"    Additional vitamin A (500 to 600 mcg retinol per day) is recommended during the first six months of lactation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/89\">",
"     89",
"    </a>",
"    ]. This supplement (resulting in a total daily dose of 1200 to 1300 mcg) is needed to compensate for the vitamin A secreted in milk and to maintain maternal hepatic stores.",
"   </p>",
"   <p>",
"    Additional vitamin E (4 mg per day alpha-tocopherol equivalents) is recommended during lactation. This supplement compensates for the secretion of vitamin E into milk.",
"   </p>",
"   <p>",
"    The vitamin K content of human milk is not affected by maternal vitamin K intake. Therefore, no additional vitamin K is required during lactation. The adequate intake (AI) is the same for lactating women and nonpregnant-nonlactating women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Water-soluble vitamins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommended dietary allowances for vitamin C and the B vitamins for lactating women exceed those of nonlactating women (",
"    <a class=\"graphic graphic_table graphicRef62755 \" href=\"mobipreview.htm?16/35/16956\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/87,90\">",
"     87,90",
"    </a>",
"    ]. These requirements account for the amount of nutrient secreted into milk and allow for metabolic inefficiencies and individual variation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Calcium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 210 mg per day of calcium is secreted in milk. Increased bone mobilization and decreased urinary excretion provide the calcium needed for milk production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/17,91\">",
"     17,91",
"    </a>",
"    ]. Intestinal calcium absorption does not appear to increase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/92,93\">",
"     92,93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Changes in calcium homeostasis are independent of maternal calcium intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/94-96\">",
"     94-96",
"    </a>",
"    ]. As an example, in one report, loss of bone mass during lactation was similar with calcium supplementation (1 g per day) and placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/94-96\">",
"     94-96",
"    </a>",
"    ]. Recovery of bone loss occurred with resumption of menses and weaning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/92,97,98\">",
"     92,97,98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because lactation-induced bone loss is not prevented by increased calcium intake, and bone loss is recovered after weaning, the dietary recommendation for calcium is the same for lactating and nonlactating women of the same age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increased bone resorption and decreased urinary excretion of phosphorus and magnesium are also independent of dietary intake during lactation. Therefore, the dietary recommendations for phosphorus and magnesium are the same as for nonlactating women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Trace minerals",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Iron &mdash; The iron secreted in milk (0.15&ndash;3.0 mg per day) is offset largely by amenorrhea. The RDA for 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for adolescents and 9",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for women was based on the basal iron needs for nonpregnant-nonlactating women, iron secreted into milk, and a coefficient of variance (CV) of 30 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Zinc &mdash; Dietary zinc (4 mg per day) required during lactation is based on the amount secreted in milk, absorption efficiency, and CV of 10 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Iodine &mdash; Dietary iodine (140 mcg per day) recommended during lactation is based on the estimated need of the infant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/89\">",
"       89",
"      </a>",
"      ]. This RDA for iodine is based on the amount secreted in milk (114",
"      <span class=\"nowrap\">",
"       mcg/day)",
"      </span>",
"      and a CV of 20 percent.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"       Selenium",
"      </a>",
"      &mdash; Additional selenium (15 mcg per day) is required to maintain an adequate concentration in milk and to prevent maternal depletion. This is based on the amount secreted in milk (14 mcg per day), and CV of 10 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/90\">",
"       90",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Fish intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fish and shellfish contribute high-quality protein and other essential nutrients including omega-3 fatty acids to the diet. Fish consumption by breastfeeding mothers has been suggested to be beneficial to the infant because fish contain large amounts of essential fatty acids, which are important in brain development. However, currently available data are insufficient to demonstrate an association between subsequent cognition in children and increased omega-3 fatty acid intake in their mothers during breastfeeding.",
"   </p>",
"   <p>",
"    However, nearly all fish and shellfish contain traces of mercury. For most people, the risk from mercury by eating fish and shellfish is not a health concern. Consumption of certain fish and shellfish by breastfeeding women may pose an increased risk to the breastfed infant's developing nervous system, since both inorganic and organic mercury are transferred from maternal serum to human milk. The mercury concentrations in human milk are highly variable and tend to decline between colostrum and mature milk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our practice, we utilize the Food and Drug Administration (FDA) and the Environmental Protection Agency (EPA) guidelines for fish intake for pregnant women, breastfeeding mothers, and young children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43864/abstract/101\">",
"     101",
"    </a>",
"    ]. The following recommendations allow the mother and their infants to receive some of the potential benefits of eating fish and shellfish, while limiting mercury intake.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Breastfeeding mothers should not eat shark, swordfish, king mackerel, or tilefish because they contain high concentrations of mercury.",
"     </li>",
"     <li>",
"      Breastfeeding mothers can eat up to 12 ounces a week (2 average servings) of fish and shellfish that have lower concentrations of mercury. They include shrimp, canned light tuna, salmon, pollock, and catfish. Albacore (white) tuna has more mercury than canned light tuna, therefore, consumption of albacore tuna should be limited to 6 ounces (one average meal) per week.",
"     </li>",
"     <li>",
"      Check local advisories about the safety of fish caught by family and friends in local lakes, rivers, and coastal areas. If no advice is available, breastfeeding mothers may eat up to 6 ounces (one average meal) per week of fish caught from local waters, but do not consume any other fish during that week.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/13/7379?source=see_link\">",
"       \"Patient information: Health and nutrition for women who breastfeed (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/54/31588?source=see_link\">",
"       \"Patient information: Maternal health and nutrition during breastfeeding (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal milk production is dependent upon mobilization of maternal stores and dietary consumption.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Changes in maternal body composition vary during breastfeeding. Typically there is a mild gradual weight loss during the first six months postpartum with preservation of lean body mass. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Maternal nutritional status'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infant demand is the major factor in determining milk volume. Maternal factors that decrease milk volume include maternal stress, anxiety, fatigue, illness, combined",
"      <span class=\"nowrap\">",
"       estrogen/progesterone",
"      </span>",
"      oral contraceptives, and smoking. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Milk volume'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lactation requires additional energy and nutrients in the maternal diet including protein, vitamins, calcium, and trace minerals. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Nutrient requirements'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fish consumption by breastfeeding women may pose an increased risk to the breastfed infant's developing nervous system, since nearly all fish and shellfish contain traces of mercury, and mercury is transferred from maternal serum to human milk. We recommend limiting fish intake in lactating mothers according to the Food and Drug Administration and the Environmental Protection Agency guidelines that limit breastfeeding mothers to 12 ounces per week (two average servings) of fish and shellfish that have lower concentrations of mercury, such as shrimp, canned light tuna, salmon, pollock, and catfish (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Fish intake'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/1\">",
"      Butte NF, Hopkinson JM. Body composition changes during lactation are highly variable among women. J Nutr 1998; 128:381S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/2\">",
"      Potter S, Hannum S, McFarlin B, et al. Does infant feeding method influence maternal postpartum weight loss? J Am Diet Assoc 1991; 91:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/3\">",
"      Brewer MM, Bates MR, Vannoy LP. Postpartum changes in maternal weight and body fat depots in lactating vs nonlactating women. Am J Clin Nutr 1989; 49:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/4\">",
"      Dugdale AE, Eaton-Evans J. The effect of lactation and other factors on post-partum changes in body-weight and triceps skinfold thickness. Br J Nutr 1989; 61:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/5\">",
"      Ohlin A, R&ouml;ssner S. Maternal body weight development after pregnancy. Int J Obes 1990; 14:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/6\">",
"      Schauberger CW, Rooney BL, Brimer LM. Factors that influence weight loss in the puerperium. Obstet Gynecol 1992; 79:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/7\">",
"      Parker JD, Abrams B. Differences in postpartum weight retention between black and white mothers. Obstet Gynecol 1993; 81:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/8\">",
"      Greene GW, Smiciklas-Wright H, Scholl TO, Karp RJ. Postpartum weight change: how much of the weight gained in pregnancy will be lost after delivery? Obstet Gynecol 1988; 71:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/9\">",
"      Prasad AS. Zinc deficiency in women, infants and children. J Am Coll Nutr 1996; 15:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/10\">",
"      Neu J. Necrotizing enterocolitis: the search for a unifying pathogenic theory leading to prevention. Pediatr Clin North Am 1996; 43:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/11\">",
"      Rookus MA, Rokebrand P, Burema J, Deurenberg P. The effect of pregnancy on the body mass index 9 months postpartum in 49 women. Int J Obes 1987; 11:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/12\">",
"      DENNIS KJ, BYTHEWAY WR. CHANGES IN BODY WEIGHT AFTER DELIVERY. J Obstet Gynaecol Br Commonw 1965; 72:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/13\">",
"      Kramer FM, Stunkard AJ, Marshall KA, et al. Breast-feeding reduces maternal lower-body fat. J Am Diet Assoc 1993; 93:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/14\">",
"      Dewey KG, Heinig MJ, Nommsen LA. Maternal weight-loss patterns during prolonged lactation. Am J Clin Nutr 1993; 58:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/15\">",
"      Motil KJ, Sheng HP, Kertz BL, et al. Lean body mass of well-nourished women is preserved during lactation. Am J Clin Nutr 1998; 67:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/16\">",
"      Motil KJ, Davis TA, Montandon CM, et al. Whole-body protein turnover in the fed state is reduced in response to dietary protein restriction in lactating women. Am J Clin Nutr 1996; 64:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/17\">",
"      Kent GN, Price RI, Gutteridge DH, et al. Human lactation: forearm trabecular bone loss, increased bone turnover, and renal conservation of calcium and inorganic phosphate with recovery of bone mass following weaning. J Bone Miner Res 1990; 5:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/18\">",
"      Lamke B, Brundin J, Moberg P. Changes of bone mineral content during pregnancy and lactation. Acta Obstet Gynecol Scand 1977; 56:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/19\">",
"      Specker BL, Tsang RC, Ho ML. Changes in calcium homeostasis over the first year postpartum: effect of lactation and weaning. Obstet Gynecol 1991; 78:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/20\">",
"      Sowers M, Corton G, Shapiro B, et al. Changes in bone density with lactation. JAMA 1993; 269:3130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/21\">",
"      Aloia JF, Cohn SH, Vaswani A, et al. Risk factors for postmenopausal osteoporosis. Am J Med 1985; 78:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/22\">",
"      Kreiger N, Kelsey JL, Holford TR, O'Connor T. An epidemiologic study of hip fracture in postmenopausal women. Am J Epidemiol 1982; 116:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/23\">",
"      Cumming RG, Klineberg RJ. Breastfeeding and other reproductive factors and the risk of hip fractures in elderly women. Int J Epidemiol 1993; 22:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/24\">",
"      Bauer DC, Browner WS, Cauley JA, et al. Factors associated with appendicular bone mass in older women. The Study of Osteoporotic Fractures Research Group. Ann Intern Med 1993; 118:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/25\">",
"      Fox KM, Magaziner J, Sherwin R, et al. Reproductive correlates of bone mass in elderly women. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1993; 8:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/26\">",
"      Kritz-Silverstein D, Barrett-Connor E, Hollenbach KA. Pregnancy and lactation as determinants of bone mineral density in postmenopausal women. Am J Epidemiol 1992; 136:1052.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine (US) Subcommittee on Lactation. Nutrition during lactation, Committee on Nutritional Status during Pregnancy and Lactation, Food and Nutrition Board, Institute of Medicine, National Academy of Sciences. National Academy Press, Washington, DC, 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/28\">",
"      Neville MC, Keller R, Seacat J, et al. Studies in human lactation: milk volumes in lactating women during the onset of lactation and full lactation. Am J Clin Nutr 1988; 48:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/29\">",
"      Macy, IG, Hunscher, HA, Donelson, E, et al. Human milk flow. Am J Dis Child 1930; 39:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/30\">",
"      Saint L, Maggiore P, Hartmann PE. Yield and nutrient content of milk in eight women breast-feeding twins and one woman breast-feeding triplets. Br J Nutr 1986; 56:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/31\">",
"      Michaelsen KF, Larsen PS, Thomsen BL, Samuelson G. The Copenhagen Cohort Study on Infant Nutrition and Growth: breast-milk intake, human milk macronutrient content, and influencing factors. Am J Clin Nutr 1994; 59:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/32\">",
"      Dewey KG, Heinig MJ, Nommsen LA, Lonnerdal B. Maternal versus infant factors related to breast milk intake and residual milk volume: the DARLING study. Pediatrics 1991; 87:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/33\">",
"      Butte NF, Garza C, Johnson CA, et al. Longitudinal changes in milk composition of mothers delivering preterm and term infants. Early Hum Dev 1984; 9:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/34\">",
"      Butte NF, Garza C, Smith EO, Nichols BL. Human milk intake and growth in exclusively breast-fed infants. J Pediatr 1984; 104:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/35\">",
"      Stuff JE, Nichols BL. Nutrient intake and growth performance of older infants fed human milk. J Pediatr 1989; 115:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/36\">",
"      Dewey KG, Heinig MJ, Nommsen LA, L&ouml;nnerdal B. Adequacy of energy intake among breast-fed infants in the DARLING study: relationships to growth velocity, morbidity, and activity levels. Davis Area Research on Lactation, Infant Nutrition and Growth. J Pediatr 1991; 119:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/37\">",
"      Schanler RJ, Hurst NM. Human milk for the hospitalized preterm infant. Semin Perinatol 1994; 18:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/38\">",
"      Hopkinson JM, Schanler RJ, Fraley JK, Garza C. Milk production by mothers of premature infants: influence of cigarette smoking. Pediatrics 1992; 90:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/39\">",
"      Vio F, Salazar G, Infante C. Smoking during pregnancy and lactation and its effects on breast-milk volume. Am J Clin Nutr 1991; 54:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/40\">",
"      Andersen AN, Lund-Andersen C, Larsen JF, et al. Suppressed prolactin but normal neurophysin levels in cigarette smoking breast-feeding women. Clin Endocrinol (Oxf) 1982; 17:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/41\">",
"      Hopkinson JM, Schanler RJ, Garza C. Milk production by mothers of premature infants. Pediatrics 1988; 81:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/42\">",
"      Butte NF, Garza C, Stuff JE, et al. Effect of maternal diet and body composition on lactational performance. Am J Clin Nutr 1984; 39:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/43\">",
"      Michaelsen KF. Nutrition and growth during infancy. The Copenhagen Cohort Study. Acta Paediatr Suppl 1997; 420:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/44\">",
"      Hennart P, Vis HL. Breast-feeding and post partum amenorrhoea in Central Africa. 1. Milk production in rural areas. J Trop Pediatr 1980; 26:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/45\">",
"      van Steenbergen WM, Kusin JA, Kardjati S, de With C. Energy supplementation in the last trimester of pregnancy in East Java, Indonesia: effect on breast-milk output. Am J Clin Nutr 1989; 50:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/46\">",
"      Brown KH, Akhtar NA, Robertson AD, Ahmed MG. Lactational capacity of marginally nourished mothers: relationships between maternal nutritional status and quantity and proximate composition of milk. Pediatrics 1986; 78:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/47\">",
"      Imong SM, Jackson DA, Wongsawasdii L, et al. Predictors of breast milk intake in rural northern Thailand. J Pediatr Gastroenterol Nutr 1989; 8:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/48\">",
"      de Kanashiro HC, Brown KH, Lopez de Roma&ntilde;a G, et al. Consumption of food and nutrients by infants in Huascar (Lima), Peru. Am J Clin Nutr 1990; 52:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/49\">",
"      Orr-Ewing AK, Heywood PF, Coward WA. Longitudinal measurements of breast milk output by a 2H2O tracer technique in rural Papua New Guinean women. Hum Nutr Clin Nutr 1986; 40:451.",
"     </a>",
"    </li>",
"    <li>",
"     Prentice, A, Paul, A, Prentice, A, et al. Cross-cultural differences in lactational performance. In: Human Lactation 2: Maternal and Environmental Factors, Hamosh M, Goldman AS (Eds), Plenum Press, New York 1986. p.13.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/51\">",
"      Butte NF, Villalpando S, Wong WW, et al. Human milk intake and growth faltering of rural Mesoamerindian infants. Am J Clin Nutr 1992; 55:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/52\">",
"      Dewey KG, Lovelady CA, Nommsen-Rivers LA, et al. A randomized study of the effects of aerobic exercise by lactating women on breast-milk volume and composition. N Engl J Med 1994; 330:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/53\">",
"      Tankeyoon M, Dusitsin N, Chalapati S, et al. Effects of hormonal contraceptives on milk volume and infant growth. WHO Special Programme of Research, Development and Research Training in Human Reproduction Task force on oral contraceptives. Contraception 1984; 30:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/54\">",
"      Hurst NM, Valentine CJ, Renfro L, et al. Skin-to-skin holding in the neonatal intensive care unit influences maternal milk volume. J Perinatol 1997; 17:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/55\">",
"      Strode MA, Dewey KG, L&ouml;nnerdal B. Effects of short-term caloric restriction on lactational performance of well-nourished women. Acta Paediatr Scand 1986; 75:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/56\">",
"      Dusdieker LB, Hemingway DL, Stumbo PJ. Is milk production impaired by dieting during lactation? Am J Clin Nutr 1994; 59:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/57\">",
"      McCrory MA, Nommsen-Rivers LA, Mol&eacute; PA, et al. Randomized trial of the short-term effects of dieting compared with dieting plus aerobic exercise on lactation performance. Am J Clin Nutr 1999; 69:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/58\">",
"      Butte NF. Dieting and exercise in overweight, lactating women. N Engl J Med 2000; 342:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/59\">",
"      Lovelady CA, Garner KE, Moreno KL, Williams JP. The effect of weight loss in overweight, lactating women on the growth of their infants. N Engl J Med 2000; 342:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/60\">",
"      L&ouml;nnerdal B, Forsum E, Gebre-Medhin M, Hambraeus L. Breast milk composition in Ethiopian and Swedish mothers. II. Lactose, nitrogen, and protein contents. Am J Clin Nutr 1976; 29:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/61\">",
"      Villalpando SF, Butte NF, Wong WW, et al. Lactation performance of rural Mesoamerindians. Eur J Clin Nutr 1992; 46:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/62\">",
"      Sanchez-Pozo A, Lopez Morales J, Izquierdo A, et al. Protein composition of human milk in relation to mothers' weight and socioeconomic status. Hum Nutr Clin Nutr 1987; 41:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/63\">",
"      Forsum E, L&ouml;nnerdal B. Effect of protein intake on protein and nitrogen composition of breast milk. Am J Clin Nutr 1980; 33:1809.",
"     </a>",
"    </li>",
"    <li>",
"     Jensen, RG. The Lipids of Human Milk. CRC Press, Boca Raton 1989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/65\">",
"      Chappell JE, Francis T, Clandinin MT. Vitamin A and E content of human milk at early stages of lactation. Early Hum Dev 1985; 11:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/66\">",
"      Hachey DL, Silber GH, Wong WW, Garza C. Human lactation. II: Endogenous fatty acid synthesis by the mammary gland. Pediatr Res 1989; 25:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/67\">",
"      Sanders TA, Ellis FR, Dickerson JW. Studies of vegans: the fatty acid composition of plasma choline phosphoglycerides, erythrocytes, adipose tissue, and breast milk, and some indicators of susceptibility to ischemic heart disease in vegans and omnivore controls. Am J Clin Nutr 1978; 31:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/68\">",
"      Butte NF, Calloway DH. Evaluation of lactational performance of Navajo women. Am J Clin Nutr 1981; 34:2210.",
"     </a>",
"    </li>",
"    <li>",
"     Hollis, BW, Lambert, PW, Horst, RL. Factors affecting the antirachitic sterol content of native milk. In: Perinatal Calcium and Phosphorous Metabolism, Holick MF, Gray TK, Anast CS. (Eds), Elsevier Science Publishers BV, Amsterdam 1983. p.157.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/70\">",
"      Greer FR, Hollis BW, Napoli JL. High concentrations of vitamin D2 in human milk associated with pharmacologic doses of vitamin D2. J Pediatr 1984; 105:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/71\">",
"      von Kries R, Shearer M, McCarthy PT, et al. Vitamin K1 content of maternal milk: influence of the stage of lactation, lipid composition, and vitamin K1 supplements given to the mother. Pediatr Res 1987; 22:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/72\">",
"      Bates CJ, Prentice AM, Prentice A, et al. The effect of vitamin C supplementation on lactating women in Keneba, a West African rural community. Int J Vitam Nutr Res 1983; 53:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/73\">",
"      Byerley LO, Kirksey A. Effects of different levels of vitamin C intake on the vitamin C concentration in human milk and the vitamin C intakes of breast-fed infants. Am J Clin Nutr 1985; 41:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/74\">",
"      PRATT JP, HAMIL BM, MOYER EZ, et al. Metabolism of women during the reproductive cycle. XVIII. The effect of multivitamin supplements on the secretion of B vitamins in human milk. J Nutr 1951; 44:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/75\">",
"      Kang-Yoon SA, Kirksey A, Giacoia G, West K. Vitamin B-6 status of breast-fed neonates: influence of pyridoxine supplementation on mothers and neonates. Am J Clin Nutr 1992; 56:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/76\">",
"      Metz J, Zalusky R, Herbert V. Folic acid binding by serum and milk. Am J Clin Nutr 1968; 21:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/77\">",
"      Johnson PR Jr, Roloff JS. Vitamin B12 deficiency in an infant strictly breast-fed by a mother with latent pernicious anemia. J Pediatr 1982; 100:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/78\">",
"      Prentice A. Calcium supplementation during breast-feeding. N Engl J Med 1997; 337:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/79\">",
"      Dallman PR. Iron deficiency in the weanling: a nutritional problem on the way to resolution. Acta Paediatr Scand Suppl 1986; 323:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/80\">",
"      Siimes MA, Salmenper&auml; L, Perheentupa J. Exclusive breast-feeding for 9 months: risk of iron deficiency. J Pediatr 1984; 104:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/81\">",
"      L&ouml;nnerdal B, Keen CL, Hurley LS. Iron, copper, zinc, and manganese in milk. Annu Rev Nutr 1981; 1:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/82\">",
"      Krebs NF, Reidinger CJ, Hartley S, et al. Zinc supplementation during lactation: effects on maternal status and milk zinc concentrations. Am J Clin Nutr 1995; 61:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/83\">",
"      Mannan S, Picciano MF. Influence of maternal selenium status on human milk selenium concentration and glutathione peroxidase activity. Am J Clin Nutr 1987; 46:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/84\">",
"      Gushurst CA, Mueller JA, Green JA, Sedor F. Breast milk iodide: reassessment in the 1980s. Pediatrics 1984; 73:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/85\">",
"      Picciano MF. Nutrient composition of human milk. Pediatr Clin North Am 2001; 48:53.",
"     </a>",
"    </li>",
"    <li>",
"     DRI, Dietary Reference Intakes: For Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients). Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food, and Nutrition Board, Institute of Medicine. National Academy Press, Washington, DC 2005.",
"    </li>",
"    <li>",
"     Standing Committee on the Scientific Evaluation of Dietary Reference Intakes IoM. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. National Academy Press, Washington DC 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/88\">",
"      Hollis BW, Wagner CL. Vitamin D requirements during lactation: high-dose maternal supplementation as therapy to prevent hypovitaminosis D for both the mother and the nursing infant. Am J Clin Nutr 2004; 80:1752S.",
"     </a>",
"    </li>",
"    <li>",
"     DRI, Dietary Reference Intakes: For Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food, and Nutrition Board, Institute of Medicine. National Academy Press, Washington, DC 2000.",
"    </li>",
"    <li>",
"     DRI, Dietary Reference Intakes: For Vitamin C, Vitamin E, Selenium, and Carotenoid. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food, and Nutrition Board, Institute of Medicine. National Academy Press, Washington, DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/91\">",
"      Specker BL, Vieira NE, O'Brien KO, et al. Calcium kinetics in lactating women with low and high calcium intakes. Am J Clin Nutr 1994; 59:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/92\">",
"      Kalkwarf HJ, Specker BL, Heubi JE, et al. Intestinal calcium absorption of women during lactation and after weaning. Am J Clin Nutr 1996; 63:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/93\">",
"      Kent GN, Price RI, Gutteridge DH, et al. The efficiency of intestinal calcium absorption is increased in late pregnancy but not in established lactation. Calcif Tissue Int 1991; 48:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/94\">",
"      Cross NA, Hillman LS, Allen SH, Krause GF. Changes in bone mineral density and markers of bone remodeling during lactation and postweaning in women consuming high amounts of calcium. J Bone Miner Res 1995; 10:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/95\">",
"      Kalkwarf HJ, Specker BL, Bianchi DC, et al. The effect of calcium supplementation on bone density during lactation and after weaning. N Engl J Med 1997; 337:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/96\">",
"      Prentice A, Jarjou LM, Cole TJ, et al. Calcium requirements of lactating Gambian mothers: effects of a calcium supplement on breast-milk calcium concentration, maternal bone mineral content, and urinary calcium excretion. Am J Clin Nutr 1995; 62:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/97\">",
"      Sowers M, Eyre D, Hollis BW, et al. Biochemical markers of bone turnover in lactating and nonlactating postpartum women. J Clin Endocrinol Metab 1995; 80:2210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/98\">",
"      Hopkinson JM, Butte NF, Ellis K, Smith EO. Lactation delays postpartum bone mineral accretion and temporarily alters its regional distribution in women. J Nutr 2000; 130:777.",
"     </a>",
"    </li>",
"    <li>",
"     DRI, Dietary reference intakes: For calcium, phosphorus, magnesium, vitamin D, and fluoride. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food, and Nutrition Board, Institute of Medicine. National Academy Press, Washington, DC 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43864/abstract/100\">",
"      D&oacute;rea JG. Exposure to mercury during the first six months via human milk and vaccines: modifying risk factors. Am J Perinatol 2007; 24:387.",
"     </a>",
"    </li>",
"    <li>",
"     United States Department of Health and Human Services and United States Enivonrmental Protection Agency. What you need to know about mercury in fish and shellfish. www.cfsan.fda.gov/~dms/admehg3.html (Accessed August 4, 2008).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4960 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-60.18.131.125-8B92F8E3C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_53_43864=[""].join("\n");
var outline_f42_53_43864=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MATERNAL NUTRITIONAL STATUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Body weight",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Lean body mass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Vitamins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Bone mineral loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MILK VOLUME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Infant demand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Maternal factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MILK COMPOSITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Energy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Protein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Fatty acids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Fat-soluble vitamins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Water-soluble vitamins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Mineral content",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      NUTRIENT REQUIREMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Energy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Protein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Fat-soluble vitamins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Water-soluble vitamins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Calcium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Trace minerals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Fish intake",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/4960\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/4960|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/32/16909\" title=\"table 1\">",
"      RDA for lactation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/35/16956\" title=\"table 2\">",
"      Vitamins lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/13/7379?source=related_link\">",
"      Patient information: Health and nutrition for women who breastfeed (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/54/31588?source=related_link\">",
"      Patient information: Maternal health and nutrition during breastfeeding (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_53_43865="Treatment of hypothyroidism";
var content_f42_53_43865=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of hypothyroidism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/53/43865/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/53/43865/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/53/43865/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/53/43865/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/53/43865/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/53/43865/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/53/43865/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most patients, hypothyroidism is a permanent condition requiring lifelong treatment. Therapy consists of thyroid hormone replacement unless the hypothyroidism is transient (as after painless thyroiditis or subacute thyroiditis) or reversible (due to a drug that can be discontinued). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/47/42744?source=see_link\">",
"     \"Disorders that cause hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The goal of therapy is restoration of the euthyroid state, which can be readily accomplished in almost all patients by oral administration of synthetic thyroxine (T4). Appropriate treatment reverses all the clinical manifestations of hypothyroidism.",
"   </p>",
"   <p>",
"    This review will discuss the major issues that must be addressed in the treatment of patients with overt primary hypothyroidism. The approach to therapy of patients with subclinical, congenital, and central hypothyroidism is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/48/3850?source=see_link\">",
"     \"Subclinical hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/46/15081?source=see_link\">",
"     \"Treatment and prognosis of congenital hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/6/18536?source=see_link\">",
"     \"Central hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STANDARD REPLACEMENT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of choice for correction of hypothyroidism is synthetic thyroxine (T4). Approximately 80 percent of a dose of T4 is absorbed and, because the plasma half-life of T4 is long (seven days), once-daily treatment results in nearly constant serum T4 and triiodothyronine (T3) concentrations when a steady state is reached [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    T4 is a prohormone with very little intrinsic activity. It is deiodinated in peripheral tissues to form T3, the active thyroid hormone. This deiodination process accounts for about 80 percent of the total daily production of T3 in normal subjects; as a result, serum T3 concentrations are within the normal range in hypothyroid patients receiving adequate T4 therapy. This was illustrated in a prospective study of recently athyreotic patients receiving T4 therapy to normalize serum TSH concentrations; serum T3 on treatment were, in most cases, comparable to the patients' pre-operative T3 values [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/2\">",
"     2",
"    </a>",
"    ]. The prohormone nature of T4 is an advantage over other thyroid hormone preparations, because the patient's own physiologic mechanisms control the production of active hormone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     T4 formulations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several formulations of T4 are available, but there has been considerable controversy about their bioequivalence. In the past, variation in the T4 content of brand-name and generic formulations led many experts to prefer a specific preparation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/3\">",
"     3",
"    </a>",
"    ]. In 1997, a study of two brand name and two generic formulations of T4, using FDA-recommended methodology for determining bioequivalence, reported that all four preparations were equivalent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/4\">",
"     4",
"    </a>",
"    ]. However, the methodology used to determine bioequivalence in the study is considered by some to be flawed since endogenous T4 concentrations were not taken into account [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2004, the FDA approved generic substitution for branded",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    products. The American Thyroid Association, Endocrine Society, and American Association of Clinical Endocrinologists opposed this decision, and recommend that patients remain on the same brand that was initially prescribed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because there may be subtle differences in bioavailability between T4 formulations, we feel that it is preferable to stay with one formulation when possible. We generally avoid generics because of the potential for frequent interchange of preparations by the pharmacy. Often, however, the generic manufacturer can be identified from the prescription label, and the patient may request refills from the same generic pharmaceutical company. If the preparation must be changed, follow-up biochemical monitoring should be done to determine if retitration of the dose is necessary. We typically measure a serum TSH six weeks after changing preparations.",
"   </p>",
"   <p>",
"    The brand-name and most generic formulations are available in color-coded tablets at small increments in hormone content to allow precise titration of the dose according to the serum concentration of thyrotropin (TSH). In addition to solid tablets, one brand preparation is available as a soft gel capsule. While the pharmacokinetics of the soft gel capsule was similar to tablets in healthy subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/7\">",
"     7",
"    </a>",
"    ], in another study the soft gel capsule was less dependent upon gastric pH than a branded tablet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adverse effects of T4 replacement are rare as long as the correct dose is given. Rare patients have an allergy to the dye or filler in the tablets. For dye sensitivities, multiples of the white 50 mcg tablets can be given.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Dose and monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The average replacement dose of T4 in adults is approximately 1.6",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    body weight per day (112",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    in a 70-kg adult), but the range of required doses is wide, varying from 50 to &ge;200",
"    <span class=\"nowrap\">",
"     mcg/day.",
"    </span>",
"    T4 requirements correlate better with lean body mass than total body weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/9\">",
"     9",
"    </a>",
"    ]. The necessary dose per kg body weight is higher in infants and children. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/46/15081?source=see_link\">",
"     \"Treatment and prognosis of congenital hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The dose may vary according to the cause of hypothyroidism. In a study of patients receiving chronic T4 therapy who were clinically euthyroid and had serum free T4 index values within the upper half of the normal range and normal serum TSH concentration, 73 patients with hypothyroidism caused by chronic autoimmune thyroiditis or radioiodine therapy were receiving less T4 (118",
"    <span class=\"nowrap\">",
"     mcg/day,",
"    </span>",
"    1.6",
"    <span class=\"nowrap\">",
"     mcg/kg/day)",
"    </span>",
"    than 36 patients with thyroid cancer after near-total thyroidectomy (152",
"    <span class=\"nowrap\">",
"     mcg/day,",
"    </span>",
"    2.1",
"    <span class=\"nowrap\">",
"     mcg/kg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/10\">",
"     10",
"    </a>",
"    ]. In 36 patients with central hypothyroidism and similar serum free T4 index values, the T4 dose was higher (155",
"    <span class=\"nowrap\">",
"     mcg/day,",
"    </span>",
"    1.9",
"    <span class=\"nowrap\">",
"     mcg/kg/day).",
"    </span>",
"    These results suggest that both normal amounts of TSH and the presence of residual thyroid tissue are determinants of T4 dose in patients with hypothyroidism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Timing of dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;T4 should be taken on an empty stomach, ideally an hour before breakfast, but few patients are able to wait a full hour. One study showed higher serum T4 and lower TSH concentrations in 90 patients receiving T4 at bedtime, but patients had nothing to eat for several hours before bedtime and were compared with patients who took it in the morning and waited only 30 minutes before breakfast [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/11\">",
"     11",
"    </a>",
"    ], suggesting the proximity to food ingestion rather than time of day is the more critical parameter. In a study of 65 patients, serum TSH concentrations were lower and less variable with standard fasting administration of T4 when compared with nonfasting administration (mean serum TSH 1.06 &plusmn; 1.23, 2.93 &plusmn; 3.29, and 2.19 &plusmn; 2.66",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    if taken one hour before breakfast, with breakfast, or at bedtime two hours after the last meal, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/12\">",
"     12",
"    </a>",
"    ], and in two small studies, coffee appeared to interfere with T4 absorption of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    tablets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/13\">",
"     13",
"    </a>",
"    ], but not soft gel capsules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    T4 should not be taken with other medications that interfere with its absorption, such as bile acid resins, proton pump inhibitors,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/11/37046?source=see_link\">",
"     ferrous sulfate",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/40/42632?source=see_link&amp;anchor=H16#H16\">",
"     \"Drug interactions with thyroid hormones\", section on 'Drugs that affect gastrointestinal absorption of thyroid hormone'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Starting dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial dose can be the full anticipated dose (1.6",
"    <span class=\"nowrap\">",
"     mcg/kg/day)",
"    </span>",
"    in young, healthy patients, but older patients should be started on a lower dose (25 to 50 mcg daily). (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Older patients or those with coronary heart disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In one prospective study of different starting doses of T4, 50 hypothyroid patients (mean age 47 years) were randomly assigned to receive a full starting dose of T4 (1.6",
"    <span class=\"nowrap\">",
"     mcg/kg/day)",
"    </span>",
"    or T4 25",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    with dose adjustments every four weeks. Euthyroidism was achieved more rapidly in the full dose group, but signs and symptoms of hypothyroidism and quality of life improved at a similar rate in the two groups. No adverse cardiac effects were seen in either group, but the subjects in the study, including elderly patients, had been carefully screened to rule out cardiovascular disease prior to enrollment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Initial monitoring and dose adjustments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are treated with T4 usually begin to improve within two weeks, but complete recovery can take several months in those with severe hypothyroidism. Although symptoms may begin to resolve after two to three weeks, steady-state TSH concentrations are not achieved for at least six weeks. Serum thyroid hormone concentrations increase first, and then TSH secretion begins to fall because of the negative feedback action of T4 on the pituitary and hypothalamus. Thus, after initiation of T4 therapy, the patient should be reevaluated and serum TSH measured in six weeks. If the TSH remains above the normal reference range, the dose of T4 can be increased by 12 to 25",
"    <span class=\"nowrap\">",
"     mcg/day.",
"    </span>",
"    The patient will require a repeat TSH measurement in six weeks.",
"   </p>",
"   <p>",
"    For patients who continue to have symptoms after two to three weeks, a serum free T4 and TSH can be measured in three weeks. If the serum free T4 is below normal, the dose can be increased in three weeks without additional testing, but it should be recognized that serum T4 (and TSH) concentrations at this time are not steady-state values, and serum TSH levels may still be falling despite normal (or even high) serum T4 concentrations. Given the one-week plasma half-life of T4, it takes about six weeks (six half-lives) before a steady state is attained after therapy is initiated or the dose is changed.",
"   </p>",
"   <p>",
"    This process of increasing the dose of T4 every three to six weeks (depending upon the patient's symptoms) should continue, based upon periodic measurements of serum TSH (and free T4 if steady state conditions have not yet been achieved), until the high values of TSH in patients with primary hypothyroidism return to the reference range. Once this is achieved, periodic monitoring is warranted. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Adjustment of maintenance dose'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Goals of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of therapy are amelioration of symptoms and normalization of TSH secretion. An additional goal in patients with goitrous autoimmune thyroiditis (Hashimoto's disease) is a reduction in the size of the goiter. Approximately 50 percent of patients have some decrease, which lags behind the fall in TSH secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is considerable controversy as to the appropriate upper limit of normal for serum TSH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/18\">",
"     18",
"    </a>",
"    ]. Most laboratories have used values of about 4.5 to 5.0",
"    <span class=\"nowrap\">",
"     mU/L.",
"    </span>",
"    However, others have argued that the upper limit of normal of the euthyroid reference range should be reduced to 2.5",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    because 95 percent of rigorously screened young euthyroid volunteers have serum values between 0.4 and 2.5",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/19\">",
"     19",
"    </a>",
"    ]. In contrast, others have reported that age-adjusted upper limits of normal for TSH should be higher than 4.5 to 5",
"    <span class=\"nowrap\">",
"     mU/L,",
"    </span>",
"    especially for patients over age 70 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/20\">",
"     20",
"    </a>",
"    ]. This topic is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3608?source=see_link&amp;anchor=H3#H3\">",
"     \"Laboratory assessment of thyroid function\", section on 'Serum TSH concentration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Until there are data demonstrating an adverse biologic significance for serum TSH values between 2.5 and 5.0",
"    <span class=\"nowrap\">",
"     mU/L,",
"    </span>",
"    the wisdom of labeling such patients as hypothyroid is questionable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/21\">",
"     21",
"    </a>",
"    ]. We aim to keep TSH within the normal reference range (approximately 0.5 to 5.0",
"    <span class=\"nowrap\">",
"     mU/L).",
"    </span>",
"    However, if a patient has possible hypothyroid symptoms, and the TSH is confirmed by repeat measurement to be at the upper limits or above the normal reference range, it is reasonable to increase the dose and to aim for a serum TSH value in the lower half of the normal range. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Persistent symptoms'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Adjustment of maintenance dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;After identification of the proper maintenance dose, the patient should be examined and serum TSH measured once yearly, or more often if there is an abnormal result or a change in the patient's status. Further dose adjustment is usually not required, but there are situations in which a different dose may be needed (",
"    <a class=\"graphic graphic_table graphicRef60325 \" href=\"mobipreview.htm?7/46/7916\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increases in dose may be required during pregnancy (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/47/14073?source=see_link&amp;anchor=H57693680#H57693680\">",
"       \"Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment\", section on 'Preexisting hypothyroidism'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Small increases also may be required in patients in whom thyroid hormone absorption is diminished (patients with impaired acid secretion or other gastrointestinal disorders), excretion is increased (nephrotic syndrome), or the rate of metabolism is increased (therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      ) (",
"      <a class=\"graphic graphic_table graphicRef60325 \" href=\"mobipreview.htm?7/46/7916\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Other factors affecting thyroid hormone metabolism'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/51/43829?source=see_link\">",
"       \"Endocrine dysfunction in the nephrotic syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/40/42632?source=see_link&amp;anchor=H16#H16\">",
"       \"Drug interactions with thyroid hormones\", section on 'Drugs that affect gastrointestinal absorption of thyroid hormone'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Small decreases in dose may be needed as patients age, after parturition, if the patient loses weight, or during androgen therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/22,23\">",
"       22,23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Long-term outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful treatment reverses all the symptoms and signs of hypothyroidism, although some neuromuscular and psychiatric symptoms may not disappear for several months. Long-term treatment of hypothyroidism is not associated with impaired cognitive function or depressed mood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/24\">",
"     24",
"    </a>",
"    ]. Limited evidence also suggests no increase in all-cause mortality among patients with treated hypothyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, infants with congenital hypothyroidism in whom treatment is inadequate or delayed for several months may have permanent brain damage, even if they are adequately treated several months later. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/46/15081?source=see_link\">",
"     \"Treatment and prognosis of congenital hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Persistent symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because many symptoms of hypothyroidism are nonspecific, patients often think that their T4 dose is inadequate when they feel tired or gain weight. The possibility of an inadequate current T4 dose should be verified by measuring serum TSH before the dose is increased. The dose need not be altered in patients who are clinically euthyroid if their serum TSH concentration is only slightly above (or below) the normal range. TSH values may be slightly high (or low) because of laboratory error or normal circadian fluctuations in TSH secretion, so a slightly high (or low) value should be confirmed with repeat measurement before the dose is changed.",
"   </p>",
"   <p>",
"    On the other hand, if a patient has possible hypothyroid symptoms, and the serum TSH is confirmed by repeat measurement to be at the upper limits or above the normal reference range, it is reasonable to increase the dose and to aim for a serum TSH value in the lower half of the normal range. However, it is important to note that there is an age-related shift towards higher TSH concentrations in older patients, with an upper limit of normal of about 7.5",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    in 80 year olds. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3608?source=see_link&amp;anchor=H3#H3\">",
"     \"Laboratory assessment of thyroid function\", section on 'Serum TSH concentration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whether or not the dose adjustment will improve symptoms is uncertain. In one study of 697 patients on thyroid hormone replacement, psychological well-being assessed by the General Health Questionnaire-12 correlated positively with serum free T4 and negatively with serum TSH for TSH values between 0.3 to 4.0",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/27\">",
"     27",
"    </a>",
"    ]. More specifically, psychological well-being was better in patients with lower serum TSH concentrations. However, in a blinded, placebo-controlled, cross-over trial, patients could not distinguish between their usual T4 dose and doses that were 25 to 50",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    higher, ie, they could not distinguish between TSH values that averaged 2.8",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    from those that averaged 0.3",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Overreplacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overreplacement with T4 should be discouraged. Overreplacement causes subclinical hyperthyroidism (normal serum T4 and T3 and low serum TSH concentrations), or even overt hyperthyroidism. The main risk of subclinical hyperthyroidism is atrial fibrillation, which occurs three times more often in older patients with serum TSH concentrations",
"    <span class=\"nowrap\">",
"     &lt;0.1mU/L",
"    </span>",
"    than in normal subjects (",
"    <a class=\"graphic graphic_figure graphicRef55024 \" href=\"mobipreview.htm?19/0/19469\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/29\">",
"     29",
"    </a>",
"    ]. Patients with subclinical hyperthyroidism, particularly postmenopausal women, may also have accelerated bone loss. It is therefore important to educate patients about the potential adverse effects of overtreatment with T4. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/22/23913?source=see_link&amp;anchor=H6#H6\">",
"     \"Subclinical hyperthyroidism\", section on 'Clinical findings'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/11/17593?source=see_link\">",
"     \"Bone disease with hyperthyroidism and thyroid hormone therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risks associated with overreplacement of thyroid hormone are greatest in those with the most suppressed TSH concentrations. This was illustrated by the findings from a cohort study of 17,684 patients taking T4 replacement therapy. Patients with TSH concentrations between 0.04 and 0.4",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    were not at risk for arrhythmias or fractures compared to those with a TSH in the normal reference range. However, patients with more severe iatrogenic hyperthyroidism (TSH &lt;0.03",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    had a significantly increased risk of arrhythmia (HR 1.6) and fractures (HR 2.0) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Combination T4 and T3 therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some hypothyroid patients remain symptomatic in spite of T4 replacement and normal serum TSH concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/31\">",
"     31",
"    </a>",
"    ]. As an example, in a large community-based questionnaire study of patients taking T4 who had normal serum TSH concentrations, 9 to 13 percent more patients had impaired psychological well being as compared with normal subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/32\">",
"     32",
"    </a>",
"    ]. This observation raises the question of whether hypothyroid patients might benefit from substitution of some T3 for T4, an idea that has now been evaluated in multiple randomized trials, almost all of which showed that combination T4-T3 therapy does not appear to be superior to T4 monotherapy for the management of hypothyroid symptoms. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/33-44\">",
"     33-44",
"    </a>",
"    ]. In some trials, patients preferred combined therapy to T4 monotherapy; however, in one of those studies, patients were given overzealous doses of thyroid hormone resulting in mild hyperthyroidism. In general, clinical trials of combination T4-T3 therapy have not successfully replicated physiologic T4-T3 production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Well-designed blinded studies are still needed to address this ongoing controversy. In addition, slow-release T3 preparations, which may avoid supraphysiologic peaks in serum T3 concentrations, have not yet been combined with T4 and compared with T4 monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/46\">",
"     46",
"    </a>",
"    ]. A combination T4-slow release T3 preparation may better replicate physiological T4-T3 production. Until more data are available, for the majority of hypothyroid patients, we do not suggest combination T4-T3 therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1402944\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a systematic review of nine randomized trials, only one trial reported beneficial effects of combination T4-T3 therapy on mood, quality of life, and psychometric performance when compared with T4 therapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/47\">",
"     47",
"    </a>",
"    ]. A subsequent meta-analysis of 11 published randomized trials including 1216 patients showed that there was no benefit (fatigue, bodily pain, anxiety, depression, quality of life) of combined therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one of the largest trials, 697 hypothyroid patients, who were treated with a stable dose of T4 and who had TSH levels in the normal laboratory reference range, were randomly assigned to partial substitution of 50 mcg T4 by 10 mcg T3 versus the original dose of T4 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/41\">",
"     41",
"    </a>",
"    ]. After three months, both groups had significant improvement compared with baseline in the General Health Questionnaire (GHQ) score. Throughout the 12 month trial, there were no significant differences in GHQ scores between the two groups. However, the substitution of a fixed dose of 10 mcg T3 for 50 mcg T4 resulted in a fall in free T4 and a rise in TSH, indicating possible under-replacement with T4 in the intervention group.",
"   </p>",
"   <p>",
"    Another double-blind randomized controlled trial comparing T4 alone to T4 and T3 in a molar ratio of 10:1 or 5:1, also failed to demonstrate improvement in mood, fatigue, psychological symptoms or neurocognitive testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/42\">",
"     42",
"    </a>",
"    ]. However, patients preferred combined therapy to T4 alone. Forty-four percent of the patients who preferred combined therapy had TSH values less than 0.11. In addition, those patients taking T4:T3 in a molar ratio of 5:1 had a 1.8 kg weight loss, which correlated with a preference for the combined treatment, and 54 percent of these patients had subnormal serum TSH concentrations.",
"   </p>",
"   <p>",
"    A re-analysis of the largest trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/41\">",
"     41",
"    </a>",
"    ] examined the relationship of polymorphisms in the type 2 deiodinase, which converts T4 to T3, with baseline psychological well-being and the response to combined T4-T3 therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/49\">",
"     49",
"    </a>",
"    ]. Sixteen percent of the population studied had the CC genotype of the rs225014 polymorphism in the deiodinase 2 gene (DIO2); these patients had worse baseline General Health Questionnaire (GHQ) scores and showed greater improvement after T4-T3 therapy compared with T4 alone. If confirmed, it appears likely that T4-T3 therapy may improve symptoms in the subgroup of patients with a polymorphism in the type 2 deiodinase.",
"   </p>",
"   <p>",
"    In addition, the available data, including a study demonstrating comparable pre- and post-T3 levels in thyroidectomized patients taking T4 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/2\">",
"     2",
"    </a>",
"    ], do not rule out the possibility that some thyroidectomized patients who have no residual endogenous T3 production might derive benefit from the addition of T3, while patients with autoimmune thyroiditis do not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     T3 containing preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid hormone preparations containing T3 alone or in combination with T4 include the following (",
"    <a class=\"graphic graphic_table graphicRef53418 \" href=\"mobipreview.htm?30/20/31051\">",
"     table 2",
"    </a>",
"    ): Cytomel (T3 alone), T4-T3 combination preparations (eg, Thyrolar), and desiccated thyroid (a mixture of T3 and T4 made from porcine thyroid glands, eg, Armour&reg; thyroid).",
"   </p>",
"   <p>",
"    For most patients with hypothyroidism, we do not suggest treatment with T3 containing preparations. Patients treated with currently available T3-containing preparations have wide fluctuations in serum T3 concentrations throughout the day due to its rapid gastrointestinal absorption and its relatively short half-life in the circulation (about one day).",
"   </p>",
"   <p>",
"    In addition, serum T4 concentrations remain low in patients treated with T3, and relatively low in those treated with preparations containing both T3 and T4; while serum TSH in steady state conditions will reflect the adequacy of therapy, measurement of serum T4 may be confusing and lead to inappropriate changes in dose.",
"   </p>",
"   <p>",
"    Temporary treatment with T3 is appropriate in patients with thyroid cancer who are to undergo radioiodine imaging and possible treatment. To shorten the period of hypothyroidism, the patient's T4 therapy is discontinued and T3 is substituted for three to four weeks until the T4 is cleared. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/13/34010?source=see_link\">",
"     \"Radioiodine treatment of differentiated thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Converting from desiccated thyroid extract to T4",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who are taking desiccated thyroid or T4-T3 combination preparations, we prefer to switch them to T4.",
"   </p>",
"   <p>",
"    In general, 1 grain of desiccated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/39/9846?source=see_link\">",
"     thyroid extract",
"    </a>",
"    (60 mg) contains about 38 mcg T4 and 9 mcg T3; 9 mcg T3 is equivalent to about 36 mcg T4, so 1 grain is equivalent to a total of about 74 mcg T4. However, to switch patients from thyroid extract to T4, many clinicians use a simple conversion factor of 1 grain = 100 mcg T4. As an example, for a patient who is taking 1&frac12; grains (90 mg) of desiccated thyroid, an equivalent T4 dose ranges from 112 to 150 mcg. Some clinicians prefer to begin with the higher dose (150 mcg) and slowly taper the dose if the TSH measured six weeks after switching remains below the reference range.",
"   </p>",
"   <p>",
"    For patients taking T4-T3 combination preparations, the equivalent dose of T4 can be calculated based upon the amount of T4 and T3 in the preparation. As an example, for a patient who is taking a preparation of 12.5 mcg T3 combined with 50 mcg T4, the equivalent dose of T4 is approximately 100 mcg (50 mcg T4 plus four times the dose of T3).",
"   </p>",
"   <p>",
"    Often, patients who are doing well symptomatically on a combination preparation (eg, Armour thyroid) refuse to be switched to T4. As long as their thyroid function tests are normal and are monitored periodically, it is probably safe for them to continue to take the thyroid preparation they prefer. Also, Armour thyroid is cheaper than most branded T4 products.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SPECIAL TREATMENT SITUATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several situations in which therapy should be more conservative or the dose may need modification:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Older patients or those with coronary heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elderly patients and those with coronary disease or multiple coronary risk factors should be treated conservatively. Thyroid hormone increases myocardial oxygen demand, which is associated with a small risk of inducing cardiac arrhythmias, angina pectoris, or myocardial infarction in older patients. In one study of 55 hypothyroid patients with angina, for example, the angina worsened in nine after the initiation of thyroid hormone therapy and did not change or improved in the others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Older patients (older than 50 or 60 years depending upon coexisting medical problems) should initially be treated with 50 mcg",
"    <span class=\"nowrap\">",
"     T4/day.",
"    </span>",
"    Those who have a history of coronary heart disease should initially be treated with 25",
"    <span class=\"nowrap\">",
"     mcg/day.",
"    </span>",
"    In either group the dose can be increased by 25",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    every three to six weeks until replacement is complete, as determined by a normal serum TSH concentration, or an increase in dose results in cardiac symptoms, in which case something less than full replacement may have to be accepted.",
"   </p>",
"   <p>",
"    Many older patients receiving thyroid hormone replacement are over- or undertreated, as illustrated by a community survey that identified 339 individuals over age 65 years taking thyroid hormone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/51\">",
"     51",
"    </a>",
"    ]. Forty-one percent of patients had a subnormal TSH; 16 percent had a high TSH; and only 43 percent were euthyroid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/51\">",
"     51",
"    </a>",
"    ]. Patients with low body weight were more likely to have a subnormal TSH, while those with diabetes were at risk for having low and high serum TSH.",
"   </p>",
"   <p>",
"    The clinical manifestations and consequences of hypothyroidism (subclinical and overt) in the elderly are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14503?source=see_link\">",
"     \"Clinical manifestations of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Hypothyroidism during pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women need more thyroid hormone during pregnancy and, unlike normal women, those with hypothyroidism are unable to increase thyroidal T4 and T3 secretion. Approximately 75 to 85 percent of women with preexisting hypothyroidism need a higher dose of T4 during pregnancy to maintain normal TSH secretion. The increase in T4 requirements occurs as early as the fifth week of gestation and plateaus by week 16 to 20. The treatment of hypothyroidism during pregnancy is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/47/14073?source=see_link&amp;anchor=H57693680#H57693680\">",
"     \"Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment\", section on 'Preexisting hypothyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Euthyroid women with thyroid peroxidase antibodies who become pregnant are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16186?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of thyroid disease in pregnancy\", section on 'Thyroid peroxidase antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Estrogen therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women receiving T4 therapy, estrogens increase serum TBG concentrations, as they do in normal women, and may increase the need for T4. In a study of postmenopausal women (25 women with hypothyroidism and 11 normal women) treated with 0.625 mg conjugated estrogens daily for 48 weeks, serum T4 and TBG concentrations increased in both the hypothyroid and normal women. Serum free T4 and TSH concentrations did not change in the normal women, but decreased and increased, respectively, in the hypothyroid women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/52\">",
"     52",
"    </a>",
"    ]. Among the latter, seven women had serum TSH concentrations &gt;7",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    and were given more T4. These data suggest that serum TSH should be measured approximately 12 weeks after starting estrogen therapy in women receiving T4 therapy to determine if an increase in T4 dose is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Other factors affecting thyroid hormone metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;When drugs that affect the catabolism or absorption of T4 are begun for coexisting medical conditions (",
"    <a class=\"graphic graphic_table graphicRef50439 \" href=\"mobipreview.htm?21/19/21820\">",
"     table 3",
"    </a>",
"    ), serum TSH should be measured four to six weeks later to confirm that the T4 dose is still adequate. The dose should be increased if the serum TSH value is high. Medications that interfere with T4 absorption should be taken several hours after the T4 dose. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/40/42632?source=see_link\">",
"     \"Drug interactions with thyroid hormones\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A high-fiber diet is another factor that can interfere with the absorption of T4 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/53\">",
"     53",
"    </a>",
"    ]. It is not known whether natural fiber-containing medications (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/26/8614?source=see_link\">",
"     psyllium",
"    </a>",
"    ) affect T4 absorption, but the synthetic fiber substitute FiberCon&copy; does not.",
"   </p>",
"   <p>",
"    Coffee, in comparison to water, reduces the absorption of tablet",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    preparations by 27 to 36 percent (assessed by the area under the curve increase in serum T4 administered simultaneously) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with autoimmune gastritis have higher T4 requirements (tablet preparations). In one study, the T4 dose was 17 percent higher in patients with parietal cell antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A polymorphism in the type 2 deiodinase has been described, which shows reduced activity. Athyreotic patients with this polymorphism required 10 percent higher doses of T4 to obtain normal TSH concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several patients who appeared to be resistant to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    administration did not absorb levothyroxine tablets well but absorbed levothyroxine tablets after they were pulverized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Surgical patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have investigated the safety of general anesthesia and surgery in patients with untreated or inadequately treated hypothyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. Surprisingly few adverse effects were reported, although the hypothyroid patients had a higher frequency of perioperative and postoperative ileus, hypotension, hyponatremia, and central nervous system dysfunction than did the euthyroid patients. They also had less fever during serious infections and increased sensitivity to anesthesia and opiate pain medications.",
"   </p>",
"   <p>",
"    Thus, urgent surgery should not be postponed in hypothyroid patients, but the patient should be managed expectantly for the complications described above. On the other hand, it is prudent to postpone surgery until the euthyroid state is restored when hypothyroidism is discovered in a patient being evaluated for elective surgery.",
"   </p>",
"   <p>",
"    Patients receiving chronic T4 therapy who undergo surgery and are unable to eat for several days need not be given T4 parenterally. If oral intake cannot be resumed in five to seven days, then T4 should be given intravenously. The dose should be approximately 70 to 80 percent of the patient's usual oral dose, because that is about the fraction of oral T4 that is absorbed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/1,60\">",
"     1,60",
"    </a>",
"    ]. We typically give 80 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Subclinical hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the serum TSH concentration is higher than 10",
"    <span class=\"nowrap\">",
"     mU/L,",
"    </span>",
"    patients with subclinical hypothyroidism should be treated with T4 to prevent progression to overt hypothyroidism. Treatment may also be indicated in non-elderly patients with TSH levels between 4.5 and 10",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    who have a goiter, nonspecific symptoms of hypothyroidism such as fatigue, constipation, or depression, or high titers of serum thyroid peroxidase (microsomal) antibodies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/48/3850?source=see_link\">",
"     \"Subclinical hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Poorly compliant patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients do not take their T4 regularly and do not respond to efforts to improve compliance. These patients may be given their total weekly dose of T4 once per week. The efficacy of this approach was evaluated in a crossover trial of 12 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/61\">",
"     61",
"    </a>",
"    ]. The mean serum TSH concentration one week after a single weekly dose was slightly higher than when the usual dose was given daily (6.6 versus 3.9",
"    <span class=\"nowrap\">",
"     mU/L),",
"    </span>",
"    but the raised value returned to normal one day after the next weekly dose. There was no difference in symptoms between daily or weekly dosing. Weekly dosing should probably not be used in patients with coronary heart disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Secondary or central hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with hypothyroidism caused by hypothalamic or pituitary disease have low serum T4 concentrations and low or normal serum TSH concentrations (a normal value is inappropriately low in the presence of hypothyroidism). A few, however, have slightly high serum TSH concentrations, because the TSH that is secreted is poorly glycosylated and has low bioactivity (but normal immunoactivity). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/6/18536?source=see_link&amp;anchor=H18020102#H18020102\">",
"     \"Central hypothyroidism\", section on 'Laboratory findings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of T4 therapy in patients with central hypothyroidism must be monitored clinically and by measurements of serum T4; measurements of serum TSH are of no value. Thus, the dose should be adjusted according to the patient's symptoms and serum T4 values, aiming to maintain the serum T4 concentration in the upper part of the normal range. Patients with central hypothyroidism may need more T4 to achieve serum T4 values in the upper half of the normal range than patients with primary hypothyroidism caused by chronic autoimmune thyroiditis or radioiodine therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/6/18536?source=see_link&amp;anchor=H13#H13\">",
"     \"Central hypothyroidism\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possible presence of other hormonal deficiencies should be kept in mind because administration of T4 to patients with unsuspected and untreated secondary adrenal insufficiency can precipitate an acute adrenal crisis. Thus, pituitary-adrenal function should be assessed, usually by an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/20/24902?source=see_link\">",
"     ACTH stimulation test",
"    </a>",
"    , before T4 therapy is begun in patients with central hypothyroidism, and glucocorticoid therapy should be given with T4 if adrenal insufficiency is present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/28/41413?source=see_link\">",
"     \"Diagnosis of hypopituitarism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Thyroid cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have had a thyroidectomy for thyroid cancer, with or without additional treatment with I-131, need to take T4 not only for treatment of hypothyroidism, but also to prevent recurrence of their thyroid cancer. T4 therapy should be life-long in these patients, and should not be discontinued even if sufficient residual normal thyroid tissue remains to provide adequate hormone secretion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/17/44313?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of the management of differentiated thyroid cancer\", section on 'Thyroid hormone suppression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Myxedema coma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myxedema coma is defined as severe hypothyroidism leading to decreased mental status, hypothermia, and other symptoms. It is a medical emergency with a high mortality rate. Fortunately, it is now a rare presentation of hypothyroidism, probably because of earlier diagnosis. The clinical presentation, diagnosis, and treatment of myxedema coma are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/23/8566?source=see_link\">",
"     \"Myxedema coma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1403162\">",
"    <span class=\"h2\">",
"     Selenium deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     Selenium",
"    </a>",
"    is required for deiodinase activity, and it has important effects on immune function. The effects of selenium deficiency on normal thyroid function are not well described. However, selenium deficiency has been shown to exacerbate both autoimmune thyroid disease and endemic cretinism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/62\">",
"     62",
"    </a>",
"    ]. Selenium supplementation reduces anti-thyroid peroxidase antibody levels, improves the ultrasound structure of the thyroid gland, and reduces the occurrence of post-partum thyroiditis in pregnant women with thyroid peroxidase antibodies, but a review of the literature fails to show any improvement in thyroid function when selenium is given to hypothyroid individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/15/248?source=see_link&amp;anchor=H9#H9\">",
"     \"Postpartum thyroiditis\", section on 'Prevention'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/26/35239?source=see_link&amp;anchor=H3908336#H3908336\">",
"     \"Treatment of Graves' orbitopathy (ophthalmopathy)\", section on 'Selenium'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     When the diagnosis of hypothyroidism is uncertain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients take thyroid hormone for questionable indications (eg, obesity or hypercholesterolemia), or the diagnosis of hypothyroidism is uncertain. In such a patient, a high serum TSH concentration suggests that the patient is hypothyroid, and the T4 dose should be increased accordingly. If, however, the serum TSH values are normal or low, the dose of thyroid hormone can be reduced by one-half and serum TSH measured again in four to six weeks. If the value is normal, the dose can be reduced further or stopped. Most patients with hypothyroidism have symptoms and a high serum TSH concentration within one month after discontinuing therapy.",
"   </p>",
"   <p>",
"    Many of these patients are reluctant to discontinue their thyroid hormone, especially if they have taken it for many years. In this case, the goal should be to provide an appropriate dose of T4 (adjusted to maintain a normal serum TSH concentration) to avoid the potential adverse cardiac and skeletal effects of overtreatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Pharmacologic use of thyroid hormone in euthyroid patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid hormone has been administered to euthyroid patients with several clinical problems in whom it was hoped that outcome would be improved. These include patients undergoing coronary artery bypass graft surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/64\">",
"     64",
"    </a>",
"    ] and those with refractory depression in an attempt to enhance the response to antidepressant drug therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=see_link\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A meta-analysis on the efficacy of thyroid hormone therapy in depressed patients was equivocal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/65\">",
"     65",
"    </a>",
"    ]. Although there was evidence for overall benefit, the analysis limited to randomized, double-blind trials revealed no benefit of T3. In addition, T3 did not help in an open-label study of patients with severe depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/66\">",
"     66",
"    </a>",
"    ]. Finally, T4 therapy in euthyroid patients with \"hypothyroid symptoms\" was no more effective than placebo in ameliorating symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/53/43865/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/54/3938?source=see_link\">",
"       \"Patient information: Hypothyroidism (underactive thyroid) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/54/15203?source=see_link\">",
"       \"Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)\"",
"      </a>",
"      )",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The treatment of choice for correction of hypothyroidism is synthetic thyroxine (T4). For the vast majority of patients with hypothyroidism, we suggest NOT using combination T4-T3 therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). T4-T3 therapy may improve symptoms in the rare subgroup of patients with a polymorphism in the type 2 deiodinase, which converts T4 to T3. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Combination T4 and T3 therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients remain on the same formulation of T4 (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We generally avoid generics because of the potential for frequent interchange of preparations by the pharmacy. If the preparation must be changed, follow-up biochemical monitoring (TSH) should be performed six weeks later to determine if retitration of the dose is necessary. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'T4 formulations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial dose can be the full anticipated dose (1.6",
"      <span class=\"nowrap\">",
"       mcg/kg/day)",
"      </span>",
"      in young, healthy patients, but older patients should be started on a lower dose (25 to 50 mcg daily). T4 should be taken on an empty stomach, ideally an hour before breakfast. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Starting dose'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Timing of dose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After initiation of T4 therapy, the patient should be reevaluated and serum TSH should be measured in six weeks, and the dose adjusted accordingly. Symptoms may begin to resolve after two to three weeks, but steady-state TSH concentrations are not achieved for at least six weeks. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Initial monitoring and dose adjustments'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goals of therapy are amelioration of symptoms and normalization of TSH secretion. We aim to keep TSH within the normal reference range (approximately 0.5 to 5.0",
"      <span class=\"nowrap\">",
"       mU/L).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Goals of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have possible hypothyroid symptoms, and a serum TSH that is confirmed by repeat measurement to be at the upper limits or above the normal reference range, we suggest increasing the dose of T4 with the aim of lowering the serum TSH value into the lower half of the normal range (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, it is important to note that there is an age-related shift towards higher TSH concentrations in older patients, with an upper limit of normal of about 7.5",
"      <span class=\"nowrap\">",
"       mU/L",
"      </span>",
"      in 80 year olds. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Persistent symptoms'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/1\">",
"      Fish LH, Schwartz HL, Cavanaugh J, et al. Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans. N Engl J Med 1987; 316:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/2\">",
"      Jonklaas J, Davidson B, Bhagat S, Soldin SJ. Triiodothyronine levels in athyreotic individuals during levothyroxine therapy. JAMA 2008; 299:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/3\">",
"      Oppenheimer JH, Braverman LE, Toft A, et al. A therapeutic controversy. Thyroid hormone treatment: when and what? J Clin Endocrinol Metab 1995; 80:2873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/4\">",
"      Dong BJ, Hauck WW, Gambertoglio JG, et al. Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism. JAMA 1997; 277:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/5\">",
"      Blakesley V, Awni W, Locke C, et al. Are bioequivalence studies of levothyroxine sodium formulations in euthyroid volunteers reliable? Thyroid 2004; 14:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/6\">",
"      American Thyroid Association, Endocrine Society, American Association of Clinical Endocrinologists. Joint statement on the U.S. Food and Drug Administration's decision regarding bioequivalence of levothyroxine sodium. Thyroid 2004; 14:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/7\">",
"      Yue CS, Scarsi C, Ducharme MP. Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms. Arzneimittelforschung 2012; 62:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/8\">",
"      Pabla D, Akhlaghi F, Zia H. A comparative pH-dissolution profile study of selected commercial levothyroxine products using inductively coupled plasma mass spectrometry. Eur J Pharm Biopharm 2009; 72:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/9\">",
"      Santini F, Pinchera A, Marsili A, et al. Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. J Clin Endocrinol Metab 2005; 90:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/10\">",
"      Gordon MB, Gordon MS. Variations in adequate levothyroxine replacement therapy in patients with different causes of hypothyroidism. Endocr Pract 1999; 5:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/11\">",
"      Bolk N, Visser TJ, Nijman J, et al. Effects of evening vs morning levothyroxine intake: a randomized double-blind crossover trial. Arch Intern Med 2010; 170:1996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/12\">",
"      Bach-Huynh TG, Nayak B, Loh J, et al. Timing of levothyroxine administration affects serum thyrotropin concentration. J Clin Endocrinol Metab 2009; 94:3905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/13\">",
"      Benvenga S, Bartolone L, Pappalardo MA, et al. Altered intestinal absorption of L-thyroxine caused by coffee. Thyroid 2008; 18:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/14\">",
"      Vita R, Saraceno G, Trimarchi F, Benvenga S. A novel formulation of L-thyroxine (L-T4) reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet formulations. Endocrine 2013; 43:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/15\">",
"      Roos A, Linn-Rasker SP, van Domburg RT, et al. The starting dose of levothyroxine in primary hypothyroidism treatment: a prospective, randomized, double-blind trial. Arch Intern Med 2005; 165:1714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/16\">",
"      Heged&uuml;s L, Hansen JM, Feldt-Rasmussen U, et al. Influence of thyroxine treatment on thyroid size and anti-thyroid peroxidase antibodies in Hashimoto's thyroiditis. Clin Endocrinol (Oxf) 1991; 35:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/17\">",
"      Hayashi Y, Tamai H, Fukata S, et al. A long term clinical, immunological, and histological follow-up study of patients with goitrous chronic lymphocytic thyroiditis. J Clin Endocrinol Metab 1985; 61:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/18\">",
"      Waise A, Price HC. The upper limit of the reference range for thyroid-stimulating hormone should not be confused with a cut-off to define subclinical hypothyroidism. Ann Clin Biochem 2009; 46:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/19\">",
"      Baloch Z, Carayon P, Conte-Devolx B, et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 2003; 13:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/20\">",
"      Vadiveloo T, Donnan PT, Murphy MJ, Leese GP. Age- and Gender-Specific TSH Reference Intervals in People With No Obvious Thyroid Disease in Tayside, Scotland: The Thyroid Epidemiology, Audit, and Research Study (TEARS). J Clin Endocrinol Metab 2013; 98:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/21\">",
"      Surks MI, Goswami G, Daniels GH. The thyrotropin reference range should remain unchanged. J Clin Endocrinol Metab 2005; 90:5489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/22\">",
"      Sawin CT, Herman T, Molitch ME, et al. Aging and the thyroid. Decreased requirement for thyroid hormone in older hypothyroid patients. Am J Med 1983; 75:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/23\">",
"      Arafah BM. Decreased levothyroxine requirement in women with hypothyroidism during androgen therapy for breast cancer. Ann Intern Med 1994; 121:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/24\">",
"      Kramer CK, von M&uuml;hlen D, Kritz-Silverstein D, Barrett-Connor E. Treated hypothyroidism, cognitive function, and depressed mood in old age: the Rancho Bernardo Study. Eur J Endocrinol 2009; 161:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/25\">",
"      Flynn RW, Macdonald TM, Jung RT, et al. Mortality and vascular outcomes in patients treated for thyroid dysfunction. J Clin Endocrinol Metab 2006; 91:2159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/26\">",
"      Bauer DC, Rodondi N, Stone KL, et al. Thyroid hormone use, hyperthyroidism and mortality in older women. Am J Med 2007; 120:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/27\">",
"      Saravanan P, Visser TJ, Dayan CM. Psychological well-being correlates with free thyroxine but not free 3,5,3'-triiodothyronine levels in patients on thyroid hormone replacement. J Clin Endocrinol Metab 2006; 91:3389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/28\">",
"      Walsh JP, Ward LC, Burke V, et al. Small changes in thyroxine dosage do not produce measurable changes in hypothyroid symptoms, well-being, or quality of life: results of a double-blind, randomized clinical trial. J Clin Endocrinol Metab 2006; 91:2624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/29\">",
"      Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994; 331:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/30\">",
"      Flynn RW, Bonellie SR, Jung RT, et al. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab 2010; 95:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/31\">",
"      Wekking EM, Appelhof BC, Fliers E, et al. Cognitive functioning and well-being in euthyroid patients on thyroxine replacement therapy for primary hypothyroidism. Eur J Endocrinol 2005; 153:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/32\">",
"      Saravanan P, Chau WF, Roberts N, et al. Psychological well-being in patients on 'adequate' doses of l-thyroxine: results of a large, controlled community-based questionnaire study. Clin Endocrinol (Oxf) 2002; 57:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/33\">",
"      Bunevicius R, Kazanavicius G, Zalinkevicius R, Prange AJ Jr. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med 1999; 340:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/34\">",
"      Walsh JP, Shiels L, Lim EM, et al. Combined thyroxine/liothyronine treatment does not improve well-being, quality of life, or cognitive function compared to thyroxine alone: a randomized controlled trial in patients with primary hypothyroidism. J Clin Endocrinol Metab 2003; 88:4543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/35\">",
"      Sawka AM, Gerstein HC, Marriott MJ, et al. Does a combination regimen of thyroxine (T4) and 3,5,3'-triiodothyronine improve depressive symptoms better than T4 alone in patients with hypothyroidism? Results of a double-blind, randomized, controlled trial. J Clin Endocrinol Metab 2003; 88:4551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/36\">",
"      Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial. JAMA 2003; 290:2952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/37\">",
"      Siegmund W, Spieker K, Weike AI, et al. Replacement therapy with levothyroxine plus triiodothyronine (bioavailable molar ratio 14 : 1) is not superior to thyroxine alone to improve well-being and cognitive performance in hypothyroidism. Clin Endocrinol (Oxf) 2004; 60:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/38\">",
"      Bunevicius R, Prange AJ. Mental improvement after replacement therapy with thyroxine plus triiodothyronine: relationship to cause of hypothyroidism. Int J Neuropsychopharmacol 2000; 3:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/39\">",
"      Cooper DS. Combined T4 and T3 therapy--back to the drawing board. JAMA 2003; 290:3002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/40\">",
"      Escobar-Morreale HF, Botella-Carretero JI, G&oacute;mez-Bueno M, et al. Thyroid hormone replacement therapy in primary hypothyroidism: a randomized trial comparing L-thyroxine plus liothyronine with L-thyroxine alone. Ann Intern Med 2005; 142:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/41\">",
"      Saravanan P, Simmons DJ, Greenwood R, et al. Partial substitution of thyroxine (T4) with tri-iodothyronine in patients on T4 replacement therapy: results of a large community-based randomized controlled trial. J Clin Endocrinol Metab 2005; 90:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/42\">",
"      Appelhof BC, Fliers E, Wekking EM, et al. Combined therapy with levothyroxine and liothyronine in two ratios, compared with levothyroxine monotherapy in primary hypothyroidism: a double-blind, randomized, controlled clinical trial. J Clin Endocrinol Metab 2005; 90:2666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/43\">",
"      Rodriguez T, Lavis VR, Meininger JC, et al. Substitution of liothyronine at a 1:5 ratio for a portion of levothyroxine: effect on fatigue, symptoms of depression, and working memory versus treatment with levothyroxine alone. Endocr Pract 2005; 11:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/44\">",
"      Nygaard B, Jensen EW, Kvetny J, et al. Effect of combination therapy with thyroxine (T4) and 3,5,3'-triiodothyronine versus T4 monotherapy in patients with hypothyroidism, a double-blind, randomised cross-over study. Eur J Endocrinol 2009; 161:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/45\">",
"      Wiersinga WM. Do we need still more trials on T4 and T3 combination therapy in hypothyroidism? Eur J Endocrinol 2009; 161:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/46\">",
"      Hennemann G, Docter R, Visser TJ, et al. Thyroxine plus low-dose, slow-release triiodothyronine replacement in hypothyroidism: proof of principle. Thyroid 2004; 14:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/47\">",
"      Escobar-Morreale HF, Botella-Carretero JI, Escobar del Rey F, Morreale de Escobar G. REVIEW: Treatment of hypothyroidism with combinations of levothyroxine plus liothyronine. J Clin Endocrinol Metab 2005; 90:4946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/48\">",
"      Grozinsky-Glasberg S, Fraser A, Nahshoni E, et al. Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 2006; 91:2592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/49\">",
"      Panicker V, Saravanan P, Vaidya B, et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J Clin Endocrinol Metab 2009; 94:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/50\">",
"      KEATING FR Jr, PARKIN TW, SELBY JB, DICKINSON LS. Treatment of heart disease associated with myxedema. Prog Cardiovasc Dis 1961; 3:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/51\">",
"      Somwaru LL, Arnold AM, Joshi N, et al. High frequency of and factors associated with thyroid hormone over-replacement and under-replacement in men and women aged 65 and over. J Clin Endocrinol Metab 2009; 94:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/52\">",
"      Arafah BM. Increased need for thyroxine in women with hypothyroidism during estrogen therapy. N Engl J Med 2001; 344:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/53\">",
"      Liel Y, Harman-Boehm I, Shany S. Evidence for a clinically important adverse effect of fiber-enriched diet on the bioavailability of levothyroxine in adult hypothyroid patients. J Clin Endocrinol Metab 1996; 81:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/54\">",
"      Checchi S, Montanaro A, Pasqui L, et al. L-thyroxine requirement in patients with autoimmune hypothyroidism and parietal cell antibodies. J Clin Endocrinol Metab 2008; 93:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/55\">",
"      Torlontano M, Durante C, Torrente I, et al. Type 2 deiodinase polymorphism (threonine 92 alanine) predicts L-thyroxine dose to achieve target thyrotropin levels in thyroidectomized patients. J Clin Endocrinol Metab 2008; 93:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/56\">",
"      Yamamoto T. Tablet formulation of levothyroxine is absorbed less well than powdered levothyroxine. Thyroid 2003; 13:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/57\">",
"      Weinberg AD, Brennan MD, Gorman CA, et al. Outcome of anesthesia and surgery in hypothyroid patients. Arch Intern Med 1983; 143:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/58\">",
"      Ladenson PW, Levin AA, Ridgway EC, Daniels GH. Complications of surgery in hypothyroid patients. Am J Med 1984; 77:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/59\">",
"      Drucker DJ, Burrow GN. Cardiovascular surgery in the hypothyroid patient. Arch Intern Med 1985; 145:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/60\">",
"      Hays MT, Nielsen KR. Human thyroxine absorption: age effects and methodological analyses. Thyroid 1994; 4:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/61\">",
"      Grebe SK, Cooke RR, Ford HC, et al. Treatment of hypothyroidism with once weekly thyroxine. J Clin Endocrinol Metab 1997; 82:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/62\">",
"      Duntas LH. Selenium and the thyroid: a close-knit connection. J Clin Endocrinol Metab 2010; 95:5180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/63\">",
"      Drutel A, Archambeaud F, Caron P. Selenium and the thyroid gland: more good news for clinicians. Clin Endocrinol (Oxf) 2013; 78:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/64\">",
"      Mullis-Jansson SL, Argenziano M, Corwin S, et al. A randomized double-blind study of the effect of triiodothyronine on cardiac function and morbidity after coronary bypass surgery. J Thorac Cardiovasc Surg 1999; 117:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/65\">",
"      Aronson R, Offman HJ, Joffe RT, Naylor CD. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry 1996; 53:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/66\">",
"      Birkenh&auml;ger TK, Vegt M, Nolen WA. An open study of triiodothyronine augmentation of tricyclic antidepressants in inpatients with refractory depression. Pharmacopsychiatry 1997; 30:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/53/43865/abstract/67\">",
"      Pollock MA, Sturrock A, Marshall K, et al. Thyroxine treatment in patients with symptoms of hypothyroidism but thyroid function tests within the reference range: randomised double blind placebo controlled crossover trial. BMJ 2001; 323:891.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7855 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-B6AD6E7C64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_53_43865=[""].join("\n");
var outline_f42_53_43865=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STANDARD REPLACEMENT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      T4 formulations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Dose and monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Timing of dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Starting dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Initial monitoring and dose adjustments",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Goals of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Adjustment of maintenance dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Long-term outcomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Persistent symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Overreplacement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Combination T4 and T3 therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1402944\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - T3 containing preparations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Converting from desiccated thyroid extract to T4",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SPECIAL TREATMENT SITUATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Older patients or those with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Hypothyroidism during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Estrogen therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Other factors affecting thyroid hormone metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Surgical patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Subclinical hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Poorly compliant patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Secondary or central hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Myxedema coma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1403162\">",
"      Selenium deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      When the diagnosis of hypothyroidism is uncertain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Pharmacologic use of thyroid hormone in euthyroid patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7855\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7855|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/0/19469\" title=\"figure 1\">",
"      Increased incidence of AF in subclinical hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7855|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/46/7916\" title=\"table 1\">",
"      Increased T4 requirement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/20/31051\" title=\"table 2\">",
"      Thyroid hormone preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/19/21820\" title=\"table 3\">",
"      Drugs and thyroid function",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/11/17593?source=related_link\">",
"      Bone disease with hyperthyroidism and thyroid hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/6/18536?source=related_link\">",
"      Central hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14503?source=related_link\">",
"      Clinical manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/28/41413?source=related_link\">",
"      Diagnosis of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/47/42744?source=related_link\">",
"      Disorders that cause hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/40/42632?source=related_link\">",
"      Drug interactions with thyroid hormones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=related_link\">",
"      Early noncardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/51/43829?source=related_link\">",
"      Endocrine dysfunction in the nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/47/14073?source=related_link\">",
"      Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3608?source=related_link\">",
"      Laboratory assessment of thyroid function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/23/8566?source=related_link\">",
"      Myxedema coma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/17/44313?source=related_link\">",
"      Overview of the management of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16186?source=related_link\">",
"      Overview of thyroid disease in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/54/15203?source=related_link\">",
"      Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/54/3938?source=related_link\">",
"      Patient information: Hypothyroidism (underactive thyroid) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/15/248?source=related_link\">",
"      Postpartum thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/13/34010?source=related_link\">",
"      Radioiodine treatment of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/22/23913?source=related_link\">",
"      Subclinical hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/48/3850?source=related_link\">",
"      Subclinical hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/46/15081?source=related_link\">",
"      Treatment and prognosis of congenital hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/26/35239?source=related_link\">",
"      Treatment of Graves' orbitopathy (ophthalmopathy)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_53_43866="ECG in pericarditis";
var content_f42_53_43866=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1272px;\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    Electrocardiogram (ECG) in pericarditis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electrocardiogram in acute pericarditis showing diffuse upsloping ST segment elevations seen best here in leads II, III, aVF, and V2 to V6. There is also subtle PR segment deviation (positive in aVR, negative in most other leads). ST segment elevation is due to a ventricular current of injury associated with epicardial inflammation; similarly, the PR segment changes are due to an atrial current of injury which, in pericarditis, typically displaces the PR segment upward in lead aVR and downward in most other leads.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Normal ECG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 594px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75&deg;.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_53_43866=[""].join("\n");
var outline_f42_53_43866=null;
var title_f42_53_43867="Causes of endometritis";
var content_f42_53_43867=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61306&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61306&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of endometritis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Acute",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        1. Nonobstetric causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pelvic inflammatory disease related to sexually transmitted organisms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pelvic inflammatory disease related to gynecologic procedures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        2. Obstetric causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Postpartum endometritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Retained products of conception",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Chronic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        1. Nonobstetric causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        A. Infectious",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Chlamydia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Tuberculosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Other organisms related to cervicitis and pelvic inflammatory disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        B. Intrauterine foreign bodies or growths",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Intrauterine device",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Submucous leiomyoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        C. Radiation related",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        D. Unknown etiology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        2. Obstetric causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Retained products of conception",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_53_43867=[""].join("\n");
var outline_f42_53_43867=null;
var title_f42_53_43868="Functional recovery after SCI by level";
var content_f42_53_43868=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F73350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F73350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Expected functional recovery following complete spinal cord injury by spinal level",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Spinal level",
"       </td>",
"       <td class=\"subtitle1\">",
"        Activities of daily living",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mobility/locomotion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C1-C4",
"       </td>",
"       <td>",
"        <p>",
"         Feeding possible with balanced forearm orthoses",
"        </p>",
"        <p>",
"         Computer access by tongue, breath, voice controls",
"        </p>",
"        <p>",
"         Weight shifts with power tilt and recline chair",
"        </p>",
"        <p>",
"         Mouth stick use",
"        </p>",
"       </td>",
"       <td>",
"        Operate power chair with tongue, chin, or breath controller",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C5",
"       </td>",
"       <td>",
"        <p>",
"         Drink from cup, feed with static splints and setup",
"        </p>",
"        <p>",
"         Oral/facial hygiene, writing, typing with equipment",
"        </p>",
"        <p>",
"         Dressing upper body possible",
"        </p>",
"        <p>",
"         Side-to-side weight shifts",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Propel chair with hand rim projections short distances on smooth surfaces",
"        </p>",
"        <p>",
"         Power chair with hand controller",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C6",
"       </td>",
"       <td>",
"        <p>",
"         Feed, dress upper body with setup",
"        </p>",
"        <p>",
"         Dressing lower body possible",
"        </p>",
"        <p>",
"         Forward weight shifts",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Bed mobility with equipment",
"        </p>",
"        <p>",
"         Level surface transfers with assistance",
"        </p>",
"        <p>",
"         Propel indoors with coated hand rims",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C7",
"       </td>",
"       <td>",
"        Independent feeding, dressing, bathing with adaptive equipment, built-up utensils",
"       </td>",
"       <td>",
"        <p>",
"         Independent bed mobility, level surface transfers",
"        </p>",
"        <p>",
"         Wheelchair use outdoors (power chair for school or work)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C8",
"       </td>",
"       <td>",
"        <p>",
"         Independent in feeding, dressing, bathing",
"        </p>",
"        <p>",
"         Bowel and bladder care with setup",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Propel chair, including curbs and wheelies",
"        </p>",
"        <p>",
"         Wheelchair-to-car transfers",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T1",
"       </td>",
"       <td>",
"        Independent in all self-care",
"       </td>",
"       <td>",
"        Transfer from floor to wheelchair",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T2-L1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Stand with braces for exercise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        L2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Potential for swing-to gait with long leg braces indoors",
"        </p>",
"        <p>",
"         Use of forearm crutches",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        L3",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Potential for community ambulation",
"        </p>",
"        <p>",
"         Potential for ambulation with short leg braces",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        L4-S1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Potential for ambulation without assistive devices",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Physical Medicine and Rehabilitation, 2nd ed, Randall Braddom (ED), WB Saunders Company, 2000. Copyright &copy;2000 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_53_43868=[""].join("\n");
var outline_f42_53_43868=null;
var title_f42_53_43869="Contents: Photodermatology";
var content_f42_53_43869=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?2/59/3006\">",
"       Dermatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Photodermatology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Photodermatology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Photodermatoses",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/20/33092\">",
"           Melasma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/32/27142\">",
"           Overview of cutaneous photosensitivity: Photobiology, patient evaluation, and photoprotection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/54/23400\">",
"           Photoaging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/63/18426\">",
"           Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/62/20455\">",
"           Polymorphous light eruption",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/39/21111\">",
"           Pseudoporphyria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/27/30136\">",
"           Sunburn",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Photoprotection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/42/33447\">",
"           Selection of sunscreen and sun-protective measures",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Phototherapy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/24/33160\">",
"           Psoralen plus ultraviolet A (PUVA) photochemotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/9/26775\">",
"           UVB therapy (broadband and narrowband)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Porphyrias",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/42/5801\">",
"           Congenital erythropoietic porphyria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/29/15834\">",
"           Erythropoietic protoporphyria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/45/41687\">",
"           Hereditary coproporphyria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/45/30421\">",
"           Porphyria cutanea tarda and hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/50/28458\">",
"           Porphyria cutanea tarda and hepatoerythropoietic porphyria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/19/28984\">",
"           Porphyrias: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/51/825\">",
"           Variegate porphyria",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-3E2BF9CC9D-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f42_53_43869=[""].join("\n");
var outline_f42_53_43869=null;
var title_f42_53_43870="RLL nodule CT";
var content_f42_53_43870=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Malignant solitary pulmonary nodule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 305px; height: 214px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patient with solitary pulmonary nodule in the right lower lobe, proven to represent a lung cancer. CT scan shows the solitary lesion in the superior segment of the right lower lobe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_53_43870=[""].join("\n");
var outline_f42_53_43870=null;
var title_f42_53_43871="Esophageal coin erosion 1";
var content_f42_53_43871=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Upper esophageal injury from ingested coin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 355px; height: 359px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 3-year-old female with upper esophageal injury from coin ingestion five days prior to evaluation. Endoscopy reveals deep ulceration and exudate at area of coin removal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Karen Murray, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_53_43871=[""].join("\n");
var outline_f42_53_43871=null;
